

Journal of Clinical Chemistry and Clinical Biochemistry

Zeitschrift für Klinische Chemie und Klinische Biochemie

Gemeinsames Organ der Deutschen, der Niederländischen, der Österreichischen und der Schweizerischen Gesellschaft für Klinische Chemie

Editors in Chief Verantwortliche Herausgeber

Johannes Büttner, Hannover Ernst Schütte, Berlin

Managing Editor Schriftleiter Friedrich Körber, Berlin

Co-ordinator for IFCC Recommendations Nils-Erik Saris, Helsinki

Editors Herausgeber

Johannes Büttner, Hannover
Jörg Frei, Lausanne
Wolfgang Gerok, Freiburg
Helmut Greiling, Aachen
Walter Guder, München
Erich Kaiser, Wien

Esso Johannes van Kampen, Groningen
Hermann Mattenheimer, Chicago
Ernst Schütte, Berlin
Dankwart Stamm, München
Hansjürgen Staudinger, Freiburg
Otto Wieland, München

Advisory Board unter Mitarbeit von

Klaus Borner, Berlin
Eckhart Buddecke, Münster
Hans-Christoph Curtius, Zürich
Manfred Doss, Marburg
Hartmut Dost, Gießen
Hans Faillard, Saarbrücken
Günther Fuchs, Berlin
Erich Gladtko, Köln
Heinz-Werner Goedde, Hamburg
Erwin Hansert, München

Hans Ludwig Kruskemper, Düsseldorf
Georg Löffler, Regensburg
Mathias M. Müller, Wien
Kurt Oette, Köln
Jean-Paul Persijn, Amsterdam
Ladislaus Róka, Gießen
Ellen Schmidt, Hannover
Ivar Trautshold †, Hannover
Gerhard Uhlenbruck, Köln

Volume 22, 1984



Walter de Gruyter · Berlin · New York

Contents/Inhaltsübersicht

Reviews/Übersicht

- Knoll, E. and Wisser, H.
Problems in the development of radio-immunoassay of catecholamines
Probleme bei der Entwicklung eines Radioimmunoassay für Katecholamine
741

Original papers/Originalarbeiten

- Agabiti-Rosei, E., Beschi, M., Castellano, M., Tosoni, S. and Signorini, C.
Plasma catecholamines assay: Comparison between fluorimetric and radioenzymatic method
Bestimmung der Catecholamine im Plasma: Vergleich zwischen fluorimetrischer und radioenzymatischer Methode 539
- Allner, R.
Rheumafaktoren und Immunglobuline als Störquellen bei einem heterogenen Enzym-Immunoassay
Rheumatoid factors and immunoglobulins as interfering factors in a heterogeneous enzyme immunoassay 759
- Amodio, P., Gatta, A. and Ruol, A.
 β_2 -Microglobulin concentration in plasma and production in liver cirrhosis
Konzentration von β_2 -Mikroglobulin im Plasma und Bildung bei Lebercirrhose 147
- Assink, H. A., Blijenberg, B. G., Boerma, G. J. M. and Leijnse, B.
The introduction of bromocresol purple for the determination of serum albumin on SMAC and ACA, and the standardization procedure
Die Einführung von Bromkresolpurpur für die Bestimmung von Albumin im Serum mit dem SMAC und dem ACA sowie das Standardisierungsverfahren 685
- Assmann, G., Jabs, H.-U., Nolte, W. and Schriewer, H.
Precipitation of LDL with sulphopolyanions:
A comparison of two methods for LDL cholesterol determination
Präzipitation von LDL mit Sulfopolyanionen:
Vergleich zweier Methoden zur LDL-Cholesterin-Bestimmung 781
- Assmann, G., Menzel, H. J., Kladetzky, R. G. and Büttner, G.
Frequency of apolipoprotein A-I mutants in the German population
Zur Häufigkeit von Apolipoprotein A-I-Mutanten in der deutschen Bevölkerung 585
- Assmann, G., Schulte, H. and Schriewer, H.
The effects of cigarette smoking on serum levels of HDL cholesterol and HDL apolipoprotein A-I
Findings of a prospective epidemiological study on employees of several companies in Westphalia, West Germany
Einfluß des Zigarettenrauchens auf die Konzentration von HDL-Cholesterin und HDL-Apolipoprotein A-I im Blutserum
Ergebnisse der prospektiven epidemiologischen Studie bei Betriebsangehörigen in Westfalen 397
- Balcke, P., Schmidt, P., Zazgornik, J., Haubenstock, A. and Kopsa, H.
In vitro synthesis of oxalic acid has no relevant influence on plasma oxalic acid levels in haemodialysis patients
In vitro-Synthese von Oxalsäure ist ohne Bedeutung für die Bestimmung von Oxalsäure im Plasma bei Hämodialysepatienten 261
- Becker, J. U.
Bestimmung der Konzentration eines neuen Antiarrhythmiums, Flecainid, im Plasma durch Hochleistungsflüssigkeitschromatographie (HPLC): Probenvorbereitung durch Extraktionssäulen
Measurement of the plasma concentration of a new antiarrhythmic agent, flecainid, using high performance liquid chromatography (HPLC) and sample preparation with extraction columns 389
- Biber, A. and Hempel, K.
Radioimmunoassay of oxidized calmodulin in chloramine-T treated tissue samples
Radioimmunologische Bestimmung von oxidiertem Calmodulin in Chloramin-T behandelten Proben 185
- Blijenberg, B. G., Brouwer, H. J., Roetering, H. A. and Leijnse, B.
Surveys of neonatal bilirubin. An evaluation
Auswertung von Ringversuchen für die Bilirubinbestimmung bei Neugeborenen 609
- Bollengier, F., Mahler, A., Clinet, G. and Delmotte, P.
Measles antibodies, anti-proteinase and plasminogen distribution in serum and plasma from patients affected with multiple sclerosis and patients affected with non-neurological diseases
Masern-Antikörper-, Proteaseinhibitoren- und Plasminogen-Verteilung in Serum und Plasma bei Patienten mit Multipler Sklerose und nicht-neurologischen Erkrankungen 653
- Bosch, Anneke M. G.
A radio-immunoassay of 19-nortestosterone using celite column chromatography
Radioimmunoassay von 19-Nortestosteron nach Säulenchromatographie an Celit 29
- Bossmann, Bärbel und Haschen, R. J.
De novo synthesis of brush border membrane enzymes during intestinal perfusion with bile salt in the rat
De novo-Synthese von Enzymen der Bürstensaummembran der Ratte während Perfusion des Darms mit Gallensalz 449
- Brechbühler, T., Kaeslin, M. and Wyler, F.
Reference values of various blood constituents in young minipigs
Referenzwerte verschiedener Blutbestandteile beim jungen Miniaturschwein 301
- Breuer, N., Domes, P., Tandon, R. and Goebell, H.
Isolierung und Quantifizierung nicht-sulfatierter und sulfatierter Gallensäuren im Stuhl
Isolation and quantification of non-sulphated and sulphated bile acids in faeces 623
- Bruchelt, G. and Schmidt, K. H.
Comparative studies on the oxidative processes during phagocytosis measured by luminol-dependent chemiluminescence
Vergleichende Untersuchungen von oxidativen Prozessen während der Phagozytose mittels Luminol-abhängiger Chemilumineszenz 1

- Costongs, G. M. P. J., Janson, P. C. W. and Brombacher, P. J.
Effects of biological and analytical variations on the appropriate use of "reference intervals" in Clinical Chemistry
Proposal of a scheme for longitudinal assessment of laboratory values
Wirkungen biologischer und analytischer Varianzen auf den angemessenen Gebrauch von „Referenzintervallen“ in der Klinischen Chemie.
Vorschlag eines Schemas zur longitudinalen Bewertung von Laboratoriumsergebnissen 613
- Dörner, K., Campos, R. and Börnsen, Susanne
Further evaluation of the SG test strip for estimation of urinary osmolality
Weitergehende Untersuchungen zur Abschätzung der Urin-Osmolalität mit dem SG-Teststreifen 419
- Dresow, B. and Delbrück, A.
The isolation and activity of growth-stimulating factors from human platelets
Zur Isolierung und Wirkung von wachstumsstimulierenden Faktoren aus menschlichen Thrombocyten 527
- Falk, U., Schmidt-Gayk, H. and Hüfner, M.
Radioimmunoassay for serum thyroglobulin designed for early detection of metastases and recurrences in the follow-up of patients with differentiated thyroid carcinoma
Radioimmunoassay für Thyreoglobulin im Serum zur Früherkennung von Rezidiven und Metastasen in der Nachsorge von Patienten mit differenzierten Schilddrüsenkarzinomen 661
- Fogh-Andersen, N., Ladefoged, J. and Møller-Petersen, J.
Renal and hepatic extraction of carboxy-terminal immunoreactive parathyrin in normal man
Renale und hepatische Extraktion von carboxyterminalem immunreaktiven Parathyrin bei Gesunden 479
- Gadow, A., Fricke, H., Strasburger, C. J. and Wood, W. G.
Synthesis and evaluation of luminescent tracers and hapten-protein conjugates for use in luminescence immunoassays with immobilised antibodies and antigens
A critical study of macro solid phases for use in immunoassay systems Part II
Synthese und Beurteilung von Lumineszenz-Markern und Hapten-Protein-Konjugaten für Lumineszenz-Immunoassays mit immobilisierten Antikörpern und Antigenen
Eine kritische Untersuchung von Makro-Festphasen zum Gebrauch in Immunoassay-Systemen, Teil II 337
- Gardiner, P. E., Gessner, H., Brätter, P., Stoepller, M. and Nürnberg, H. W.
The distribution of zinc in human erythrocytes
Die Verteilung von Zink in menschlichen Erythrocyten 159
- Garth, H. und Zoch, E.
Kontinuierliche Messung der katalytischen Aktivität von Adenosin-deaminase mit der pH-Stat-Methode
The continuous measurement of adenosine deaminase activity by the pH-stat-method 769
- Golf, S. W. and Graef, V.
Rat liver 3-oxo-5 α -steroid Δ^4 -dehydrogenase. Modulation of enzyme activity by changes in phosphorylation state
Modulation der Enzymaktivität der 3-Oxo-5 α -steroid Δ^4 -Dehydrogenase aus der Rattenleber durch Veränderung des Phosphorylierungszustandes 705
- Golf, S. W., Happel, O., Graef, V. and Seim, K. E.
Plasma aldosterone, cortisol and electrolyte concentrations in physical exercise after magnesium supplementation
Aldosteron-, Cortisol- und Elektrolytkonzentrationen im Plasma bei körperlicher Belastung unter Magnesiumsubstitution 717
- Golf, S. W., Kaul-Kunz, C. and Róka, L.
Creatine kinase isoenzyme MB determination on the ACA: Dependence on serum matrix and other effectors
Bestimmung der katalytischen Aktivität von Kreatinkinase Isoenzym MB mit dem ACA:
Abhängigkeit von der Serummatrix und anderen Effektoren 751
- Golf, S. W., Temme, H., Kempf, K. D., Bleyl, H., Brüstle, A., Bödeker, R. and Heinrich, D.
Systemic short-term fibrinolysis with high-dose streptokinase in acute myocardial infarction: Time course of biochemical parameters
Systemische Kurzzeitlyse mit hochdosierter Streptokinase bei Patienten mit akutem Myokardinfarkt: Verlauf der biochemischen Kenngrößen 723
- Gressner, A. M.
Aminoterminal propeptides of type III procollagen in human cerebrospinal fluid
Aminoterminal Propeptide von Typ III Prokollagen im Liquor cerebrospinalis des Menschen 237
- Gressner, A. M. and Peltzer, Birgit
Amidolytic and immuno-nephelometric determination of α_1 -proteinase inhibitor and α_2 -macroglobulin in serum with calculation of specific inhibitor activities in health and disease
Amidolytische und immun-nephelometrische Bestimmung von α_1 -Proteinase Inhibitor and α_2 -Makroglobulin im Serum mit Berechnung der spezifischen inhibitorischen Aktivitäten bei Gesunden und Kranken 633
- Gruhl, H. und Mayer, H.
Einfache und rasche Bestimmung von Thiopental im Serum mit HPLC
A simple and rapid determination of serum thiopental by HPLC 385
- Guder, W. G., Pürschel, Susanne, Vandelwalle, A. and Wirthensohn, Gabriele
Bioluminescence procedures for the measurement of NAD(P) dependent enzyme catalytic activities in submicrogram quantities of rabbit and human nephron structures
Biolumineszenzverfahren zur Messung NAD(P)abhängiger Enzymaktivitäten in einzelnen Nephronstrukturen der Kaninchen und Menschen 129
- Günther, T., Vormann, J. and Merker, H. J.
Effect of magnesium injection on foetal development
Wirkung von Magnesium-Injektionen auf die Foetalentwicklung 473
- Hagemeier, E., Kemper, K., Boos, K.-S. and Schlimme, E.
Development of a chromatographic method for the quantitative determination of minor ribonucleosides in physiological fluids
Characterization and quantitative determination of minor ribonucleosides in physiological fluids, Part I
Entwicklung einer chromatographischen Methode zur quantitativen Bestimmung seltener Ribonucleoside in physiologischen Flüssigkeiten
Charakterisierung und quantitative Bestimmung von seltenen Ribonucleosiden in physiologischen Flüssigkeiten, Teil I 175
- Hansert, E., Federkiel, H. and Stamm, D.
A new procedure for discriminating between two patient populations using multivariate decision limits:
Application in the detection and exclusion of alcoholism based on clinical laboratory findings
Neues Verfahren zur Diskrimination zweier Patientenstichproben unter Verwendung multivariater Entscheidungsgrenzen:
Anwendung zur Erkennung und zum Ausschluß des Alkoholismus aufgrund klinisch-chemischer Befunde 791
- Heinemann, G., Schivelbein, H. und Richter, Fridrun
Die analytische und diagnostische Validität der Bestimmung von Carboxyhämoglobin im Blut und Kohlenmonoxid in der Atemluft von Rauchern und Nichtraucherern
Analytic and diagnostic validity of the determination of carboxyhaemoglobin in blood, and carbon monoxide in breath of smokers and non-smokers 229
- Henkel, E., Morich, Susanne and Henkel, Renate
2-Chloro-4-nitrophenyl- β -D-maltoheptaoside:
A new substrate for the determination of α -amylase in serum and urine
2-Chlor-4-nitrophenyl- β -D-maltoheptaosid:
Ein neues Substrat zur Bestimmung von α -Amylase in Serum und Harn 489

- Hijikata, Yasuyo, Hara, Katsuko, Shiozaki, Yasuko, Murata, Kenjiro and Sameshima, Yoshiko
Determination of free tryptophan in plasma and its clinical applications
Bestimmung des freien Tryptophan im Plasma und ihre klinische Anwendung 291
- Höfeler, H. and Klingemann, H.-G.
Fibronectin and factor VIII-related antigen in liver cirrhosis and acute liver failure
Fibronectin und Faktor VIII-assoziiertes Antigen bei Lebercirrhose und akutem Leberversagen 15
- Hutt, V., Klör, H. U., Wechsler, J. G. und Ditschuneit, H.
Zusammensetzung der Lipoproteinfraktionen VLDL, LDL und HDL bei Hyperlipämikern der Typen IIa, IIb, III, IV und V im Vergleich zu Stoffwechselgesunden
Composition of VLDL, LDL and HDL lipoprotein fractions in type IIa, IIb, III, IV and V hyperlipaemic patients and in normal individuals 141
- Javeri, Shailaja and Uhlenbruck, G.
Isolation of a β -galactosidase from chicken liver
Isolierung einer β -Galaktosidase aus Hühnerleber 735
- Jelić, Z., Majkić-Singh, N., Spasić, S., Todorović, P. and Živanov-Stakić, D.
Effects of analgesic and antirheumatic drugs on the assay of serum enzymes
Einfluß analgetischer und antirheumatischer Medikamente auf die Bestimmung von Enzymen im Serum 559
- Jung, K., Pergande, Monika, Reinholdt, Carmen, Schulze, B., Scholz, D. and Strobel, V.
Multiple forms of alanine aminopeptidase, alkaline phosphatase and γ -glutamyltransferase in urine of healthy persons, patients suffering from kidney diseases and patients with kidney transplants
Multiple Formen der Alaninaminopeptidase, alkalischen Phosphatase und γ -Glutamyltransferase im Urin von gesunden Personen, Patienten mit Nierenerkrankungen und nierentransplantierten Patienten 523
- Juretić, Dubravka, Lipovac, K., Hadžija, M. and Slijepčević, M.
Effect of the degree of hyperglycaemia on the catalytic activities of glycosidases in kidney and urine of diabetic rats
Einfluß des Hyperglykämie-Grades auf die katalytischen Aktivitäten von Glykosidasen in Nieren und Harn diabetischer Ratten 21
- Kattermann, R., Jaworek, D. and Möller, G. in collaboration with Assmann, G., Björkhem, I., Svensson, L., Borner, K., Boerma, G., Leijnse, B., Desager, J. P., Harwengt, C., Kupke, Irene and Trinder, P.
Multicentre study of a new enzymatic method of cholesterol determination
Multizentrische Erprobung einer neuen enzymatischen Cholesterinbestimmung 245
- Kley, H. K. und Rick, W.
Einfluß von Lagerung und Temperatur auf die Analyse von Steroiden in Plasma und Blut
Influence of storage and temperature on steroid analysis in plasma and blood 371
- Kley, H. K., Schlaghecke, R. and Krüskemper, H. L.
The measurement of androst-4-en-17 β -ol-3,11-dione (11-oxotestosterone) by radioimmunoassay in human plasma
Radioimmunoassay zur Messung von Androst-4-en-17 β -ol-3,11-dion (11-Oxotestosteron) im Plasma des Menschen 461
- Kochen, W., Sprunck, H. P., Tauscher, B. and Klemens, M.
Five doubly unsaturated metabolites of valproic acid in urine and plasma of patients on valproic acid therapy
Fünf zweifach ungesättigte Metabolite der Valproinsäure in Urin und Plasma von epileptischen Patienten unter Behandlung mit Valproinsäure 309
- Kossmann, K. T.
Hochauflösende zweidimensionale Gelelektrophorese:
Eine Methode für das klinisch-chemische Laboratorium
High resolution two dimensional gel electrophoresis: A method for the clinical chemistry laboratory 253
- Knoll, E., Müller, F. W., Ratge, D., Bauersfeld, W. and Wisser, H.
Influence of food intake on concentrations of plasma catecholamines and cortisol
Einfluß der Nahrungsaufnahme auf die Konzentrationen von Katecholaminen und Cortisol im Plasma 597
- Knüppel, W., Neumeier, D., Fateh-Moghadam, A. und Knedel, M.
Rechnerunterstützte Befundung von Eiwweißelektrophoresen auf Celluloseacetatfolie
Computer assisted interpretative reporting for serum protein electrophoresis on cellulose acetate film 407
- Kreuzfelder, E., Kuwert, E., Windeck, R., Graben, N., Pistor, K. und Heber, F.
Radioimmuntest zur Bestimmung von Humanmyoglobin: Untere Nachweisgrenze, Präzision, Verlaufskontrolle beim myoglobininurischen Nierenversagen
A radioimmunoassay for human myoglobin:
Lower detection limit, precision, and use in following the course of myoglobinuric kidney failure 61
- Külpmann, W. R., Gey, S., Beneking, M., Kohl, B. and Oellerich, M.
Determination of total and free phenytoin in serum by non-isotopic immunoassays and gas chromatography
Bestimmung von Gesamt- und freiem Phenytoin im Serum mit radioaktivitätsfreien Immunoassays und Gaschromatographie 773
- Lapin, A., Endler, A. T., Ogunyemi, E. O. and Gabl, F.
Two dimensional electrophoresis method for additional characterization of paraproteins in serum
Clinical application of two dimensional electrophoresis, I
Zweidimensionale Elektrophorese-Methode für eine zusätzliche Charakterisierung von Paraproteinen
Klinische Anwendung von zweidimensionaler Elektrophorese, I 53
- Lindena, J., Büttner, D. and Trautschold, I.
Biological, analytical and experimental components of variance in a long-term study of plasma constituents in rat
Biologische, analytische und experimentelle Varianzkomponenten von Plasmaparametern in einer Langzeitstudie bei der Ratte 97
- Lizana, J. and Olsson, I.
High resolution isoelectric focusing in a narrow pH interval for the phenotyping of vitamin D-binding protein (Gc-globulin)
Hochauflösende isoelektrische Fokussierung in einem engen pH-Bereich zur Phänotypisierung des Vitamin D bindenden Proteins (Gc-Globulin) 545
- Manz, B., Rehder, Marianne, Heubner, A., Krienberg, R., Grill, H.-J. and Pollow, K.
17 β -Carboxamide steroids: Highly effective inhibitors of the phytohaemagglutinin mediated blastogenesis of normal human peripheral lymphocytes
17 β -Carboxamid-Steroide: Hochwirksame Inhibitoren der phytohämagglutinin-induzierten Blastogenese normaler peripherer menschlicher Lymphocyten 209
- Marwaha, R. K. and Johnson, B. F.
A radioimmunoassay for digoxin in human urine
Radioimmunoassay für Digoxin im Harn des Menschen 403
- Masson, P. and Hultberg, B.
Action pattern of serum amylase using *p*-nitrophenyl-maltoheptaoside as substrate
Wirkungs-Muster von Amylase im Serum bei Anwendung von *p*-Nitrophenyl-maltoheptaosid als Substrat 427
- Matsumoto, Akira and Fujita, Takuo
Abnormalities in erythrocyte membrane protein in pseudohypoparathyroidism type 1
Abweichungen im Proteinspektrum der Erythrocytenmembran bei Pseudohypoparathyreoidismus Typ 1 281

- Mössner, Ellen, Pfeleiderer, G. and Dittel, K. D.
Placental alkaline phosphatase in tumour tissue and serum
Placentare alkalische Phosphatase in Tumorgewebe und Serum 467
- Nägele, U., Hägele, E. O., Sauer, G., Wiedemann, E., Lehmann, P., Wahlefeld, A. W. and Gruber, W.
Reagent for the enzymatic determination of serum total triglycerides with improved lipolytic efficiency
Reagenz zur enzymatischen Bestimmung von Triglyceriden im Serum mit verbesserter lipolytischer Wirksamkeit 165
- Neuhäuser, M., Göttmann, U. und Bäßler, K. H.
Über den Einfluß der Nahrungszusammensetzung auf die Ausscheidung von 3-Methylhistidin und Kreatinin im Harn
Dietary effects on the urinary excretion of 3-methylhistidine and creatinine 731
- Neumann, S., Gunzer, G., Hennrich, N. and Lang, H.
"PMN-elastase assay":
Enzyme immunoassay for human polymorphonuclear elastase complexed with α_1 -proteinase inhibitor
"PMN-Elastase Assay":
Enzymimmunoassay zur Bestimmung des Komplexes von menschlicher Granulozyten-Elastase mit α_1 -Proteinase-inhibitor 693
- Panteghini, M. and Bonora, R.
Evaluation of a new continuous colorimetric method for determination of serum pseudocholinesterase catalytic activity and its application to a centrifugal fast analyser
Bewertung einer neuen kontinuierlichen kolorimetrischen Methode zur Bestimmung der katalytischen Aktivität von Pseudocholinesterase im Serum und ihre Anwendung an einem Zentrifugal-Analysengerät 671
- Panteghini, M., Malchiodi, A., Calarco, M. and Bonora, R.
Clinical and diagnostic significance of aspartate aminotransferase isoenzymes in sera of patients with liver diseases
Klinische und diagnostische Bedeutung von Aspartataminotransferase-Isoenzymen im Serum von Patienten mit Lebererkrankungen 153
- Parviainen, Markku T., Koivula, Timo and Jokela, Hannu
Serum amylase and isoamylase assay on the Hitachi 705 automatic clinical chemical analyzer
Bestimmung von Amylase und Isoamylase im Serum mit dem Hitachi 705 41
- Passing, H. and Bablok, W.
Comparison of several regression procedures for method comparison studies and determination of sample sizes
Application of linear regression procedures for method comparison studies in Clinical Chemistry, Part II
- Vergleich verschiedener Regressionsverfahren für Methodenvergleichsstudien und Bestimmung von Stichprobenumfängen
Methodenvergleichsstudien in der Klinischen Chemie, Teil II 431
- Ratnaike, R. N., Buttery, J. E. and Hoffmann, Sheryl
Blood ammonia measurement using a simple reflectometer
Bestimmung von Ammoniak im Blut mit einem einfachen Reflektometer 105
- Rehpenning, W., Harm, K., Ringe, J.-D., Bützow, G. H. und Voigt, K. D.
Quasi-verteilungsfreie multivariate Beurteilung klinisch-chemischer Kenngrößen mit Hilfe der X-Transformation von *van der Waerden*
Quasi-distribution-free multivariate assessment of patients' data with the aid of the X-transformation of *van der Waerden* 319
- Rick, W. und Hockeborn, M.
Katalytische Aktivität der Serumlipase im kontinuierlichen titrimetrischen Test in Abhängigkeit von der Temperatur
The effect of temperature on the catalytic activity of serum lipase in the continuous titrimetric assay 357
- Rijn, H. J. M. van, Kruit, W. H. J. and Schrijver, J.
Haptoglobin typing, is it clinically necessary for a reliable determination of haptoglobin with the single radial immunodiffusion technique?
Ist die Haptoglobin-Typisierung klinisch erforderlich für eine zuverlässige Bestimmung von Haptoglobin mit der einfachen radialen Immunodiffusion? 109
- Rydén, S., Hultberg, B., Isaksson, A. and Hafström, Lo
Influence on plasma β -N-acetyl-D-glucosaminidase of reticuloendothelial stimulation and depression: An experimental study in rats
Einfluß von Stimulation und Depression des reticuloendothelialen Systems auf die katalytische Konzentration der β -N-Acetyl-D-glucosaminidase im Plasma: Eine experimentelle Untersuchung an Ratten 219
- Sabinski, Frauke and Wosiewitz, U.
The sugar spectrum of human cholesterol gallstones, mixed and pigment gallstones:
Combined quantitative analysis of neutral sugars, N-acetylhexosamines, hexuronic and N-acetylneuraminic acids by capillary gas-liquid chromatography
Das Zuckerspektrum von Cholesterin-Gallensteinen, gemischten Gallensteinen und erdigen Pigment-Gallensteinen: Kombinierte quantitative Analyse der Neutralzucker, N-Acetylhexosamine, Hexuronsäuren und der N-Acetylneuraminsäure mit Hilfe der Kapillargaschromatographie 453
- Schädlich, H.-J., Bliersbach, Y., Felgenhauer, K. und Schifferdecker, M.
Immunglobulin G synthetisierende Lymphocyten im Liquor bei Multipler Sklerose und nichtentzündlichen Erkrankungen des Nervensystems
Occurrence of immunoglobulin G-synthesizing lymphocytes in cerebrospinal fluid in multiple sclerosis and non-inflammatory diseases of the nervous system 483
- Schleicher, E. and Wieland, O. H.
Changes of human glomerular basement membrane in diabetes mellitus
Änderungen der menschlichen glomerulären Basalmembran bei Diabetes mellitus 223
- Scholer, A. and Hohenwallner, W.
Evaluation of a colorimetric test for the determination of α -amylase with *p*-nitrophenylheptaoside as substrate
Evaluierung eines kontinuierlichen Farbstests zur Bestimmung von α -Amylase mit *p*-Nitrophenylmaltoheptaosid als Substrat 677
- Schriewer, H., Assmann, G., Sandkamp, M. and Schulte, H.
The relationship of lipoprotein (a) (Lp(a)) to risk factors of coronary heart disease:
Initial results of the prospective epidemiological study on company employees in Westfalia
Beziehung von Lipoprotein (a) (Lp(a)) zu Risikofaktoren der koronaren Herzkrankheit:
Erste Ergebnisse der prospektiven epidemiologischen Studie bei Betriebsangehörigen in Westfalen 591
- Schriewer, H., Kohnert, U. and Assmann, G.
Determination of LDL cholesterol and LDL apolipoprotein B following precipitation of VLDL in blood serum with phosphotungstic acid/MgCl₂
Bestimmung von LDL-Cholesterin und LDL-Apolipoprotein B nach Fällung von VLDL im Blutserum mittels Phosphorwolframsäure/MgCl₂ 35
- Schriewer, H., Schulte, H. and Assmann, G.
HDL phosphatidyl choline and risk factors of coronary heart disease
HDL-Phosphatidylcholin und Risikofaktoren der koronaren Herzkrankheit 515
- Seeger, W., Róka, L. and Moser, U.
Detection of organic hydroperoxidases in rabbit lung lavage fluid, but not in lung tissue homogenate, using GSH peroxidase and GSH reductase
Messung organischer Hydroperoxide in Kaninchenlungen-Lavageflüssigkeit, aber nicht im Lungengewebe-Homogenat, mittels GSH-Peroxidase und GSH-Reduktase 711

- Shamberger, R. J.
Serum sialic acid in normals and in cancer patients
Sialinsäure im Serum von Gesunden und Patienten mit Carcinomen 647
- Shin, Y. S., Stern, C., Rücker, A. v. and Endres, W.
Glycated haemoglobin and glycated albumin:
Evaluation of different methods in diabetic control
Glykosyliertes Hämoglobin und glykosyliertes Albumin:
Erprobung verschiedener Methoden bei der Diabeteskontrolle 47
- Siekmann, L.
Determination of oestradiol-17 β in human serum by isotope dilution-mass spectrometry
Definitive methods in Clinical Chemistry, II
Bestimmung von Ostradiol-17 β im menschlichen Serum mit Hilfe der massenspektrometrischen Isotopenverdünnungsanalyse
Definitive Methoden in der klinischen Chemie, II 551
- Spincemaille, J., Delanghe, J., Buyzere, M. De, Breemeersch, M. and Blaton, V.
Evaluation of three current methods for the determination of creatine kinase-MB catalytic activity
Vergleich von drei gebräuchlichen Methoden zur Bestimmung der katalytischen Aktivität von Kreatinkinase 603
- Stamm, D., Hansert, E. and Feuerlein, W.
Detection and exclusion of alcoholism in men on the basis of clinical laboratory findings
Erkennung oder Ausschluß des Alkoholismus bei Männern aufgrund klinisch-chemischer Befunde 79
- Stamm, D., Hansert, E. and Feuerlein, W.
Exzessive consumption of alcohol in men as a biological influence factor in clinical laboratory investigations
Der übermäßige Alkoholkonsum von Männern als Einflußgröße bei klinisch-chemischen Untersuchungen 65
- Sulman, Ch., Gosselin, P., Carpentier, Ph. and Lemaire, B.
Value of the estimation of thyroglobulin levels in the surveillance of treated differentiated thyroid carcinoma
Der Wert der Bestimmung der Thyroglobulinkonzentration für die Überwachung des behandelten differenzierten Schilddrüsenkarzinoms 215
- Tandt, W. R. Den and Brossmer, R.
Determination of methylumbelliferyl-N-acetylneuraminic acid sialidase for clinical purposes
Bestimmung der Methylumbelliferyl-N-acetylneuraminsäure spaltenden sauren Sialidase für klinische Zwecke 189
- Tsuboi, Seiji, Uda, Naoto, Ikeda, Mikiko, Hirota, Kazuhiro and Ohmori, Shinji
S-(1,2-Dicarboxyethyl)glutathione and S-(1,2-dicarboxyethyl)L-cysteine in lens
S-(1,2-Dicarboxyethyl)glutathion und S-(1,2-Dicarboxyethyl)L-cystein in der Linse des Auges 285
- Uhlhaas, S. und Olek, K.
Quantitative fluorimetrische Bestimmung der 4-Aminobuttersäure aus Liquor mit einem Aminosäureanalyser
Quantitative fluorimetrische measurement of 4-aminobutyric acid in human cerebrospinal fluid with an amino acid analyser 379
- Weisweiler, P. and Schwandt, P.
Determination of human apolipoproteins A-I, B, and E by laser nephelometry
Bestimmung der Humanapolipoproteine A-I, B and E durch Lasernephelometrie 113
- Wood, W. G., Fricke, H., Haritz, J., Gadow, A., Krausz, Heidi-Susanne, Tode, Bettina, Strasburger, C. J. and Scriba, P. C.
An evaluation of four different luminescence immunoassay systems: CELIA (chemiluminescent immunoassay), SPALT (solid-phase antigen luminescence technique), ILMA (immunoluminometric assay) and ILSA (immunoluminometric labelled second antibody)
A critical study of macro solid phase for use in immunoassay systems, Part III
Beurteilung von vier verschiedenen Lumineszenz-Immunoassays: CELIA (chemiluminescent immunoassay), SPALT (solid-phase antigen luminescence technique), ILMA (immunoluminometric assay) and ILSA (immunoluminometric labelled second antibody)
Eine kritische Untersuchung von Makro-Festphasen zum Gebrauch in Immunoassay-Systemen, Teil III 349
- Zweens, J. and Frankena, Henny
Simultaneous determination of dimethadione and trimethadione by infrared-spectrometry:
Application for mean intracellular pH measurement
Simultane Bestimmung von Di- und Trimethadion durch Infrarot-Spektrometrie:
Anwendung zur Bestimmung des mittleren intrazellulären pH 641

Short communications/Kurzmitteilungen

- Harder, A., Widjaja, F. and Debuch, H.
Studies on lipids from liver and spleen of a child (O.L.) with *Niemann-Pick's* disease type C
Untersuchung der Leber- und Milzlipide eines Kindes (O.L.) mit *Niemann-Pick'scher* Erkrankung 199
- Klingmüller, V., Bergmann, Eva und Claßen, P.
Alaninaminopeptidase-Ausscheidung bei Kindern: Referenzbereiche und der Einfluß nierengängiger Kontrastmittel
The urinary excretion of alanine aminopeptidase in children: Reference values and influence of nephrotropic contrast media 787
- Laing, I. A., Young, R. J. and Westwood, A.
Biochemical observations on a non-elite marathon runner
Biochemische Beobachtungen an einem Nicht-Elite-Marathonläufer 535
- Tuttlebee, J. W.
A comparison of automated and manual radioimmunoassays for the estimation of serum digoxin
Vergleich von mechanisierten und manuellen Radioimmunoassays für die Bestimmung von Digoxin im Serum 119
- Uldall, A.
Analyte and matrix problems in the calibration and quality assessment of the bromocresol green method for albumin in serum
Analyt- und Matrix-Probleme bei der Kalibrierung und Qualitätskontrolle der Bromkresolgrün-Methode für Albumin im Serum 305
- Weber, J. A.
The enzymatic determination of urea using the Greiner G 300
Enzymatische Bestimmung von Harnstoff mit dem Greiner G 300 195

Workshop conference report/Kleinkonferenz-Berichte

<p>Haeckel, R. Statistische Probleme beim Vergleich klinisch-chemischer Analysenverfahren Bericht über die Kleinkonferenz der Deutschen Gesellschaft für Klinische Chemie am 9. und 10. Juni 1983 in Bremen</p>	<p>Statistical problems in the comparison of methods of clinical chemical analysis Report on the workshop conference of the German Society for Clinical Chem- istry held on June 9 and 10, 1983 in Bremen</p>
565	265

IFCC Sections/IFCC-Sektionen

<p>Bechtler, G., Haeckel, R., Lappe, H. and Tausch, W. † Guidelines (1984) for listing specifi- cations of spectrometers in Clinical Chemistry Richtlinien (1984) zur Auflistung von Spezifikationen von Spektrometern in der Klinischen Chemie</p>	<p>Teil 3. Auswahl und Beurteilung unter Verwendung von Referenzmaterialien. Allgemeine Überlegungen</p>	<p>Beurteilung der Leistungsfähigkeit von Reagenzbestecks für die Diagnostik in Laboratorien mit begrenzten Mitteln Appendix A: Glucose</p>
565	573	827
<p>Galteau, M. M. and Siest, G. Drug effects in Clinical Chemistry. Part 2. Guidelines for evaluation of ana- lytical interference Effekte von Medikamenten in der Klini- schen Chemie. Teil 2. Richtlinien für die Feststellung analytischer Störungen</p>	<p>Logan, J. E., Bayse, D. D., Koedam, J. C., Mather, A. and Wilding, P. IFCC/WHO principles and recommen- dations on evaluation of diagnostic reagent sets used in health laboratories with limited resources. Part 4. Evaluation of performance using reference materials of analytes com- monly determined in blood serum or plasma IFCC/WHO-Prinzipien und -Empfeh- lungen zur Beurteilung von Reagenz- bestecks für die Diagnostik in Labora- torien mit begrenzten Mitteln. Teil 4. Beurteilung der Leistungsfähig- keit mit Referenzmaterialien für ge- wöhnlich in Serum oder Plasma be- stimmte Bestandteile</p>	<p>PetitClerc, C. and Wilding, P. The theory of reference values, Part 2. Selection of individuals for the produc- tion of reference values Theorie der Referenzwerte, Teil 2. Auswahl von Probanden für die Bestim- mung von Referenzwerten</p>
275	817	203
<p>Logan, J. E., Bayse, D. D., Koedam, J. C., Mather, A. and Wilding, P. IFCC/WHO principles and recommen- dations on evaluation of diagnostic reagent sets used in health laboratories with limited resources Part 3. Selection and evaluation using reference materials. General considera- tions IFCC/WHO-Prinzipien und -Empfeh- lungen zur Beurteilung von Reagenz- bestecks für die Diagnostik in Labora- torien mit begrenzten Mitteln</p>	<p>Logan, J. E., Bayse, D. D., Koedam, J. C., Mather, A. and Wilding, P. Evaluation of performance of diagnostic reagent sets used in health laboratories with limited resources Appendix A: Glucose</p>	<p>Siest, G. and Dawkins, S. J. Drug effects in Clinical Chemistry. Part I. The basic concepts Effekte von Medikamenten in der Klini- schen Chemie. Teil 1. Grundlegende Überlegungen</p>
275	497	271
		<p>Worth, H. G. J. A basic education and training frame- work for Medical Laboratory Techni- cians in Clinical Chemistry Rahmen für die Grundausbildung und Weiterbildung von Medizinischen La- boratoriumsassistenten in Klinischer Chemie</p>
		497

Letters to the Editors/ Briefe an die Herausgeber

On acid phosphatase in serum	
Letter	Dalen, A. van
Reply	Seiler, D. and Tritschler, W.
Final comment	Dalen, A. van 331
On serum total hydroxyproline assay	
Letter	Struck, H.
Reply	Gilbertson, T. J.
Final comment	Struck, H. 124

History of Clinical Chemistry/ Geschichte der Klinischen Chemie

Kattermann, R. <i>Walter Siegfried Loewe</i> (1884–1963) Sein Beitrag zur Analytik, Biologie und Pharmakologie der Sexualhormone <i>Walter Siegfried Loewe</i> (1884–1963) His contribution to the analysis, biology and pharmacology of the sex hormones	505
---	-----

Honours/Ehrungen

Ladislaus Róka 65 Jahre alt	
Ladislaus Róka 65 years of age	703
Hansjürgen Staudinger 70 Jahre alt	
Hansjürgen Staudinger 70 years of age	701

Award/Preisverleihung

Preis „Biochemische Analytik“ verliehen an <i>E. M. Southern</i> Prize “Biochemical Analysis” awarded to <i>E. M. Southern</i>	394
---	-----

**Workshop conference of the German Society for Clinical Chemistry
Immunological Diagnostics**

Bohner, J. and Stein, W. Immunological procedures in clinical enzyme diagnostics Immunologische Verfahren in der klinischen Enzymdiagnostik	943	Müller-Hermelink, H. K. and Hansmann, M.-L. Immunohistochemical procedures: Applications and problems Immunhistochemische Methoden: Ihre Anwendung und Probleme	953	Wagener, C. Diagnostic sensitivity, diagnostic specificity and predictive value of the determination of tumour markers Diagnostische Empfindlichkeit, diagnostische Spezifität und prädiktiver Wert der Bestimmung von Tumormarkern	969
Dwenger, A. Radioimmunoassay: An overview Radioimmunoassay: Ein Überblick	883	Oellerich, M. Enzyme-immunoassay: A review Enzym-Immunoassay: Eine Übersicht	895	Wonigkeit, K. Diagnostic concepts in clinical organ transplantation: Histocompatibility testing and T cell monitoring Immunologische Diagnostik bei Organtransplantationen: Histokompatibilitätstestung und T-Zell-Monitoring	959
Falkenberg, F. W., Pierard, Dany, Mai, U. and Kantwerk, Gudrun Polyclonal and monoclonal antibodies as reagents in biochemical and in clinical-chemical analysis Polyklonale und monoklonale Antikörper als Reagenzien in der biochemischen und klinisch-chemischen Analytik	867	Valet, G., Rüssmann, L. and Wirsching, R. Automated flow-cytometric identification of colo-rectal tumour cells by simultaneous DNA, CEA-antibody and cell volume measurements Automatische Identifizierung colorektaler Tumorzellen mit Hilfe simultaner durchflußcytometrischer Messung von DNA, CEA-Antikörpern und Zellvolumen	935	Wood, W. G. Luminescence immunoassays: Problems and possibilities Lumineszenz-Immunoassays: Probleme und Anwendung	905
Henkel, E. Marker-free immunological analytical methods Markerfreie immunologische Analyseverfahren	919	Vogt, W. An evaluation of immunological methods based on the requirements of the Clinical Chemist Wertigkeit immunologischer Methoden aus der Sicht des Klinischen Chemikers	927		
Kuss, E. Physikalisch-chemische Aspekte immunologischer und anderer reversibler Assoziations-Reaktionen Physical chemical aspects of immunological reactions and other reversible associations	851				

**Recommendations of the German Society for Clinical Chemistry/
Empfehlungen der Deutschen Gesellschaft für Klinische Chemie**

Durchführung klinisch-chemischer Untersuchungen bei der Prüfung von Arzneimitteln Performance of clinical-chemical tests on pharmaceuticals	811
--	-----

Obituary/Nachruf

In memoriam Ivar Trautschold	847
------------------------------	-----

Acknowledgement / Danksagung

Acknowledgement/Danksagung	980
----------------------------	-----

Allen, R. C., Bienvu, J., Laurent, P. and Suskind, R. M. Marker Proteins in Inflammation	502
---	-----

Beal, J. L. and Reinhard, E. Natural Products as Medicinal Agents	448
--	-----

Bertsch, W., Jennings, W. G. and Kaiser, R. E. Recent Advances in Capillary Gas Chromatography. Vols. 1 and 2.	583
---	-----

**Recommendations of the Deutsche Forschungsgemeinschaft/
Empfehlungen der Deutschen Forschungsgemeinschaft**

Empfehlungen für die Installation einer Gaschromatographie-Massenspektrometrie-Kopplung für klinisch-toxikologische Laboratorien Recommendations for the installation of a gas chromatography/mass spectrometry combination for clinical toxicological laboratories	699
--	-----

Book Reviews/Buchbesprechungen

Brown, S. N. An Introduction to Spectroscopy for Biochemists	447
---	-----

Brown, S. S. and Davies, D. S. Organ-Directed Toxicity – Chemical Indices and Mechanisms – Proceedings of the Symposium on Chemical Indices and Mechanisms of Organ-Directed Toxicity, Barcelona, 4–7 March 1981	447
---	-----

Guest Editorial/Gast-Editorial

Oellerich, M. Workshop conference of the German Society for Clinical Chemistry Immunological Diagnostics Introduction Kleinkonferenz der Deutschen Gesellschaft für Klinische Chemie Immunologische Diagnostik Einführung	845
---	-----

Erratum

Im Beitrag von E. Kuss, diese Z. 22, 1984, pp. 851–865 muß der Name Kirchoff richtig lauten <i>Kirchhoff</i> . In the paper by E. Kuss, this j. 22, 1984 pp. 851–865 the name Kirchoff should read <i>Kirchhoff</i> .	
--	--

Drazil, J. v. Quantities and Units of Measurement. A Dictionary and Handbook	446
---	-----

Eastham, R. D. D. Interpretation klinisch-chemischer Laborresultate. 2. Aufl.	503
--	-----

Engel, P. C. Enzyme Kinetics – The Steady-State Approach. 2nd Edition	447
--	-----

- Gräsbeck, R. and Alström, T.
Reference Values in Laboratory Medicine. The Current State of the Art. 583
- Gut, I., Cikri, M. and Plaa, G. L.
Proceedings in Life Sciences. Industrial and Environmental Xenobiotics Metabolism and Pharmacokinetics of Organic Chemistry and Metals 502
- Karow, A. M. and Pegg, D. E.
Organ Preservation for Transplantation. 2nd Edition 503
- Klämbt, D. and Heitmann, I.
Grundriß der Molekularbiologie 503
- Lamy, J. and Lamy, J.
Invertebrate Oxygen-Binding Proteins. Structure, Active Site, and Function 502
- Miescher, P. A., Bolis, L. and Torrigiani, G.
The Menarini Series on Immunopathology. Vol. 3. Immunogenetics 583
- Rosenfeld, L.
Origins of Clinical Chemistry. The Evolution of Protein Analysis 447
- Stich, H. F. and San, R. H. C.
Topics in Environmental Physiology and Medicine. Short-Term Tests for Chemical Carcinogens 448

General Index/Gesamtregister

Authors' Index/Autorenregister

- Agabiti-Rosei, E. 539
Allner, R. 759
Amodio, P. 147
Assink, H. A. 685
Assmann, G. 397, 585, 781
Assmann, G. s. Kattermann, R. 245
Assmann, G. s. Schriewer, H. 35, 515, 591
- Bablok, W. s. Passing, H. 431
Bäßler, K. H. s. Neuhäuser, M. 731
Balcke, P. 261
Bauersfeld, W. s. Knoll, E. 597
Bayse, D. D. s. Logan, J. E. 573, 817, 827
Bechtler, G. 565
Becker, J. U. 389
Beneking, M. s. Külpmann, W. R. 773
Bergmann, E. s. Klingmüller, V. 787
Beschi, M. s. Agabiti-Rosei, E. 539
Biber, A. 185
Björkhem, I. s. Kattermann, R. 245
Blaton, V. s. Spincemaille, J. 603
Bleyl, H. s. Golf, S. W. 723
Bliersbach, Y. s. Schädlich, H.-J. 483
Blijenberg, B. G. 609
Blijenberg, B. G. s. Assink, H. A. 685
Bödeker, R. s. Golf, S. W. 723
Boerma, G. s. Assink, H. A. 685
Boerma, G. s. Kattermann, R. 245
Börnsen, S. s. Dörner, K. 419
Bohner, J. 943
Bollengier, F. 653
Bonora, R. s. Panteghini, M. 153, 671
Boos, K.-S. s. Hagemeyer, E. 175
Borner, K. s. Kattermann, R. 245
Bosch, A. M. G. 29
Bossmann, B. 449
Brätter, P. s. Gardiner, P. E. 159
Brechtbühler, T. 301
Breemeersch, M. s. Spincemaille, J. 603
Breuer, N. 623
Brombacher, P. J. s. Costongs, G. M. P. J. 613
Brossmer, R. s. Tandt, W. R. Den 189
Brouwer, H. J. s. Blijenberg, B. C. 609
Bruchelt, G. 1
Brüstle, A. s. Golf, S. W. 723
Büttner, D. s. Lindena, J. 97
Büttner, G. s. Assmann, G. 585
- Bützow, G. H. s. Rehpenning, W. 319
Buttery, J. E. s. Ratnaike, R. N. 105
Buyzere, M. De s. Spincemaille, J. 603
- Calarco, M. s. Panteghini, M. 153
Campos, R. s. Dörner, K. 419
Carpentier, Ph. s. Sulman, Ch. 215
Castellano, M. s. Agabiti-Rosei, E. 539
Claaßen, P. s. Klingmüller, V. 787
Clinet, G. s. Bollengier, F. 653
Costongs, G. M. P. J. 613
- Dalen, A. van 331, 333
Dawkins, S. J. s. Siest, G. 271
Debuch, H. s. Harder, A. 199
Delanghe, J. s. Spincemaille, J. 603
Delbrück, A. s. Dresow, B. 527
Delmotte, P. s. Bollengier, F. 653
Desager, J. P. s. Kattermann, R. 245
Ditschuneit, H. s. Hutt, V. 141
Dittel, K. D. s. Mössner, E. 467
Dörner, K. 419
Dommes, P. s. Breuer, N. 623
Dresow, B. 527
Dwenger, A. 883
- Endler, A. T. s. Lapin, A. 53
Endres, W. s. Shin, Y. S. 47
- Falk, U. 661
Falkenberg, F. W. 867
Fateh-Moghadam, A. s. Knüppel, W. 407
Federkiel, H. s. Hansert, E. 791
Felgenhauer, K. s. Schädlich, H.-J. 483
Feuerlein, W. s. Stamm, D. 65, 79
Fogh-Andersen, N. 479
Frankena, H. s. Zweens, J. 641
Fricke, H. s. Gadow, A. 337
Fricke, H. s. Wood, W. G. 349
Fujita, T. s. Matsumoto, A. 281
- Gabl, F. s. Lapin, A. 53
Gadow, A. 337
Gadow, A. s. Wood, W. G. 349
Galteau, M. M. 275
Gardiner, P. E. 159
Garth, H. 769
Gatta, A. s. Amodio, P. 147
Gessner, H. s. Gardiner, P. E. 159
Gey, S. s. Külpmann, W. R. 773
Gilbertson, T. J. 124
- Goebell, H. s. Breuer, N. 623
Göttmann, U. s. Neuhäuser, M. 731
Golf, S. W. 705, 717, 723, 751
Gosselin, P. s. Sulman, Ch. 215
Graben, N. s. Kreuzfelder, E. 61
Graef, V. s. Golf, S. W. 705, 717
Gressner, A. M. 237, 633
Grill, H.-J. s. Manz, B. 209
Gruber, W. s. Nägele, U. 165
Gruhl, H. 385
Guder, W. G. 129
Günther, T. 473
Gunzer, G. s. Neumann, S. 693
- Hadžija, M. s. Juretić, D. 21
Haeckel, R. 265
Haeckel, R. s. Bechtler, G. 565
Hafström, L. s. Rydén, S. 219
Hägele, E. O. s. Nägele, U. 165
Hagemeyer, E. 175
Hansert, E. 791
Hansert, E. s. Stamm, D. 65, 79
Hansmann, M.-L. s. Müller-Hermelink, H. K. 953
Happel, O. s. Golf, S. W. 717
Hara, K. s. Hijikata, Y. 291
Harder, A. 199
Haritz, J. s. Wood, W. G. 349
Harm, K. s. Rehpenning, W. 319
Harwengt, C. s. Kattermann, R. 245
Haschen, R. J. s. Bossmann, B. 449
Haubenstock, A. s. Balcke, P. 261
Heber, F. s. Kreuzfelder, E. 61
Heinemann, G. 229
Heinrich, D. s. Golf, S. W. 723
Hempel, K. s. Biber, A. 185
Henkel, E. 489, 919
Henkel, R. s. Henkel, E. 489
Hennrich, N. s. Neumann, S. 693
Heubner, A. s. Manz, B. 209
Hijikata, Y. 291
Hirota, K. s. Tsuboi, S. 285
Hockeborn, M. s. Rick, W. 357
Höfeler, H. 15
Hoffmann, S. s. Ratnaike, R. N. 105
Hohenwallner, W. s. Scholer, A. 677
Hüfner, M. s. Falk, U. 661
Hultberg, B. s. Masson, P. 427
Hultberg, B. s. Rydén, S. 219
Hutt, V. 141
- Ikeda, M. s. Tsuboi, S. 285
Isaksson, A. s. Rydén, S. 219
- Jabs, H.-U. s. Assmann, G. 781
- Janson, P. C. W. s. Costongs, G. M. P. J. 613
Javeri, S. 735
Jaworek, D. s. Kattermann, R. 245
Jelić, Z. 559
Johnson, B. F. s. Marwaha, R. K. 403
Jokela, H. s. Parviainen, M. T. 41
Jung, K. 523
Juretić, D. 21
- Kaeslin, M. s. Brechtbühler, T. 301
Kantwerk, G. s. Falkenberg, F. W. 867
Kattermann, R. 245, 505
Kaul-Kunz, C. s. Golf, S. W. 751
Kemper, K. s. Hagemeyer, E. 175
Kempf, K. D. s. Golf, S. W. 723
Kladetzky, R. G. s. Assmann, G. 585
Klemens, M. s. Kochen, W. 309
Kley, H. K. 371, 461
Klingemann, H.-G. s. Höfeler, H. 15
Klingmüller, V. 787
Klör, H. U. s. Hutt, V. 141
Knedel, M. s. Knüppel, W. 407
Knoll, E. 597, 741
Knüppel, W. 407
Kochen, W. 309
Koedam, J. C. s. Logan, J. E. 573, 817, 827
Kohl, B. s. Külpmann, W. R. 773
Kohnert, U. s. Schriewer, H. 35
Koivula, T. s. Parviainen, M. T. 41
Kopsa, H. s. Balcke, P. 261
Kossmann, K. T. 253
Krausz, H.-S. s. Wood, W. G. 349
Kreienberg, R. s. Manz, B. 209
Kreuzfelder, E. 61
Krüskemper, H. L. s. Kley, H. K. 461
Kruit, W. H. J. s. Rijn, H. J. M. van 109
Külpmann, W. R. 773
Kupke, I. s. Kattermann, R. 245
Kuss, E. 851
Kuwert, E. s. Kreuzfelder, E. 61
- Ladefoged, J. s. Fogh-Andersen, N. 479
Laing, I. A. 535
Lang, H. s. Neumann, S. 693
Lapin, A. 53
Lappe, H. s. Bechtler, G. 565
Lehmann, P. s. Nägele, U. 165

- Leijnse, B. s. Assink, H. A. 685
 Leijnse, B. s. Blijenberg, B. G. 609
 Leijnse, B. s. Kattermann, R. 245
 Lemaire, B. s. Sulman, Ch. 215
 Lindena, J. 97
 Lipovac, K. s. Juretić, D. 21
 Lizana, J. 545
 Logan, J. E. 573, 817, 827
- Maass, G. s. Vogel, R. 847
 Mahler, A. s. Bollengier, F. 653
 Mai, U. s. Falkenberg, F. W. 867
 Majkić-Singh, N. s. Jelić, Z. 559
 Malchiodi, A. s. Panteghini, M. 153
 Manz, B. 209
 Marwaha, R. K. 403
 Masson, P. 427
 Mather, A. s. Logan, J. E. 573, 817, 827
 Matsumoto, A. 281
 Mayer, H. s. Gruhl, H. 385
 Menzl, H. J. s. Assmann, G. 585
 Merker, H. J. s. Günther, T. 473
 Möller, G. s. Kattermann, R. 245
 Møller-Petersen, J. s. Fogh-Andersen, N. 479
 Mössner, E. 467
 Morich, S. s. Henkel, E. 489
 Moser, U. s. Seeger, W. 711
 Müller, F. W. s. Knoll, E. 597
 Müller-Hermelink, H. K. 953
 Murata, K. s. Hijikata, Y. 291
- Nägele, U. 165
 Neuhäuser, M. 731
 Neumann, S. 693
 Neumeier, D. s. Knüppel, W. 407
 Nolte, W. s. Assmann, G. 781
 Nürnberg, H. W. s. Gardiner, P. E. 159
- Oellerich, M. 845, 895
 Oellerich, M. s. Külpmann, W. R. 773
 Ogunyemi, E. O. s. Lapin, A. 53
 Ohmori, S. s. Tsuboi, S. 285
 Olek, K. s. Uhlhaas, S. 379
 Olsson, I. s. Lizana, J. 545
- Panteghini, M. 153, 671
 Parviainen, M. T. 41
 Passing, H. 431
 Peltzer, B. s. Gressner, A. M. 633
 Pergande, M. s. Jung, K. 523
 PetitClerc, C. 203
 Pfeleiderer, G. s. Mössner, E. 467
 Pierard, D. s. Falkenberg, F. W. 867
 Pistor, K. s. Kreuzfelder, E. 61
 Pollow, K. s. Manz, B. 209
 Pürschel, S. s. Guder, W. G. 129
- Ratge, D. s. Knoll, E. 597
 Ratnaike, R. N. 105
 Rehder, M. s. Manz, B. 209
 Rehpenning, W. 319
 Reinholdt, C. s. Jung, K. 523
 Richter, F. s. Heinemann, G. 229
 Rick, W. 357
 Rick, W. s. Kley, H. K. 371
 Rijn, H. J. M. van 109
 Ringe, J.-D. s. Rehpenning, W. 319
 Roetering, H. A. s. Blijenberg, B. G. 609
 Róka, L. s. Golf, S. W. 751
 Róka, L. s. Seeger, W. 711
 Rücker, A. v. s. Shin, Y. S. 47
 Rüssmann, L. s. Valet, G. 935
 Ruol, A. s. Asmodio, P. 147
 Rydén, S. 219
- Sabinski, F. 453
 Sameshima, Y. s. Hijikata, Y. 291
 Sandkamp, M. s. Schriewer, H. 591
 Sauer, G. s. Nägele, U. 165
 Schädlich, H.-J. 483
 Schievelbein, H. s. Heinemann, G. 229
 Schifferdecker, M. s. Schädlich, H.-J. 483
 Schlaghecke, R. s. Kley, H. K. 461
 Schleicher, E. 223
 Schlimme, E. s. Hagemeyer, E. 175
 Schmidt, K. H. s. Bruchelt, G. 1
 Schmidt, P. s. Balcke, P. 261
 Schmidt-Gayk, H. s. Falk, U. 661
- Scholer, A. 677
 Scholz, D. s. Jung, K. 523
 Schriewer, H. 35, 515, 591
 Schriewer, H. s. Assmann, G. 397, 781
 Schrijver, J. s. Rijn, H. J. M. van 109
 Schulte, H. s. Assmann, G. 397
 Schulte, H. s. Schriewer, H. 515, 591
 Schulze, B. s. Jung, K. 523
 Schwandt, P. s. Weisweiler, P. 113
 Scriba, P. C. s. Wood, W. G. 349
 Seeger, W. 711
 Seiler, D. 331
 Seim, K. E. s. Golf, S. W. 717
 Shamberger, R. J. 647
 Shin, Y. S. 47
 Shiozaki, Y. s. Hijikata, Y. 291
 Siekmann, L. 551
 Siest, G. 271
 Siest, G. s. Galteau, M. M. 275
 Signorini, C. s. Agabiti-Rosei, E. 539
 Slijepčević, M. s. Juretić, D. 21
 Spasić, S. s. Jelić, Z. 559
 Spincemaille, J. 603
 Sprunck, H. P. s. Kochen, W. 309
 Stamm, D. 65, 79
 Stamm, D. s. Hansert, E. 791
 Stein, W. s. Bohner, J. 943
 Stern, C. s. Shin, Y. S. 47
 Stoeppler, M. s. Gardiner, P. E. 159
 Strasburger, C. J. s. Gadow, A. 337
 Strasburger, C. J. s. Wood, W. G. 349
 Strobelt, V. s. Jung, K. 523
 Struck, H. 123, 125
 Sulman, Ch. 215
 Svensson, L. s. Kattermann, R. 245
- Tandon, R. s. Breuer, N. 623
 Tandt, W. R. Den 189
 Tausch, W. † s. Bechtler, G. 565
 Tauscher, B. s. Kochen, W. 309
 Temme, H. s. Golf, S. W. 723
 Tode, B. s. Wood, W. G. 349
 Todorović, P. s. Jelić, Z. 559
 Tosoni, S. s. Agabiti-Rosei, E. 539
 Trautschold, I. s. Lindena, J. 97
 Trinder, P. s. Kattermann, R. 245
- Tritschler, W. s. Seiler, D. 331
 Tsuboi, S. 285
 Tuttlebee, J. W. 119
- Uda, N. s. Tsubori, S. 285
 Uhlhaas, S. 379
 Uhlenbruck, G. s. Javeri, S. 735
 Uldall, A. 305
- Valet, G. 935
 Vandewalle, A. s. Guder, W. G. 129
 Vogel, R. 847
 Vogt, W. 927
 Voigt, K. D. s. Rehpenning, W. 319
 Vormann, J. s. Günther, T. 473
- Wagener, C. 969
 Wahlefeld, A. W. s. Nägele, U. 165
 Weber, J. A. 195
 Wechsler, J. G. s. Hutt, V. 141
 Weisweiler, P. 113
 Westwood, A. s. Laing, I. A. 535
 Widjaja, F. s. Harder, A. 199
 Wiedemann, E. s. Nägele, U. 165
 Wieland, O. H. s. Schleicher, E. 223
 Wilding, P. s. Logan, J. E. 573, 817, 827
 Wilding, P. s. PetitClerc, C. 203
 Windeck, R. s. Kreuzfelder, E. 61
 Wirsching, R. s. Valet, G. 935
 Wirthensohn, G. s. Guder, W. G. 129
 Wisser, H. s. Knoll, E. 597, 741
 Wonigkeit, K. 959
 Wood, W. G. 349, 905
 Wood, W. G. s. Gadow, A. 337
 Worth, H. G. J. 497
 Wosiewitz, U. s. Sabinski, F. 453
 Wyler, F. s. Brechbühler, T. 301
- Zazgornik, J. s. Balcke, P. 261
 Živanov-Stakić, D. s. Jelić, Z. 559
 Zoch, E. s. Garth, H. 769
 Zweens, J. 641
- Young, R. J. s. Laing, I. A. 535

Subject Index/Sachregister

- ABEI-H 337, 349
 absorbance
 —, molar lineic 489
 —, 2-chloro-4-nitrophenol 489
 accuracy
 —, radioimmunoassay 883
- β -N-acetyl-D-glucosaminidase
 —, kidney 21
 —, diabetes mellitus 21
 —, plasma 219
 —, urine 21
 —, diabetes mellitus 21
 acetylsalicylic acid 559
- acetylsalicylic acid
 —, interference 559
 —, enzyme assays 559
 acidic α_1 -glycoprotein
 —, myocardial infarction 723
 —, fibrinolysis by streptokinase 723
- acridine 905
 action pattern
 —, α -amylase 427
 activation energy
 —, triglyceride hydrolysis 357
 —, by lipase 357
 Adair equation 851

- adenosine
 -, assay 175
 adenosine deaminase
 -, pH-stat method 769
 adenyl cyclase
 -, regulatory component 281
 --, erythrocyte 281
 adrenaline 539
 affinity
 -, definition 851
 age dependence
 -, laboratory values 613
 alanine aminopeptidase
 -, brush border membrane 449
 -, urine 523, 787
 --, and contrast media 787
 alanine aminotransferase 153
 -, assay 559
 --, drug interference 559
 -, myocardial infarction 723
 --, fibrinolysis by streptokinase 723
 albumin
 -, bromocresol green 685
 -, bromocresol purple 685
 -, glycation 223
 -, glycated 47
 -, plasma 301
 --, minipig 301
 -, serum 305
 --, bromocresol green method 305
 albuminuria 223
 alcohol
 -, consumption, excessive 65
 --, influence factor 65
 ---, biological 65
 alcoholism
 -, clinical laboratory findings 791
 -, detection 791
 --, clinical laboratory findings 791
 -, frequency 79
 -, men 79
 --, detection 79
 ---, by clinical laboratory findings 79
 --, exclusion 79
 ---, by clinical laboratory findings 79
 aldosterone
 -, blood 371
 -, plasma 371, 717
 --, physical exercise 717
 Allen-Doisy test 505
 AMETIA 895
 amidolytic assay
 -, proteinase inhibitors 633
 amino acids
 -, metabolism 535
 --, marathon runner 535
 4-aminobutyric acid
 -, cerebrospinal fluid 379
 --, fluorimetry 379
 aminophenazone
 -, interference 559
 --, enzyme assays 559
 ammonia
 -, blood 105
 --, reflectometer 105
 amylase
 -, inhibitor 41
 --, wheat 41
 amylase
 -, serum 41
 --, *p*-nitrophenyl- α -*D*-maltoheptaoside 41
 α -amylase
 -, assay 677
 --, *p*-nitrophenylheptaoside 677
 -, serum 427, 489
 --, 2-chloro-4-nitrophenyl- β -*D*-maltoheptaoside 489
 --, *p*-nitrophenyl-maltoheptaoside 427
 ---, action pattern 427
 -, urine 489
 --, 2-chloro-4-nitrophenyl- β -*D*-maltoheptaoside 489
 analgesics
 -, interference 559
 --, enzyme assays 559
 analytes
 -, determination 65
 --, influence factor 65
 ---, alcohol consumption 65
 androgens
 -, detection methods 505
 androst-4-en-17 β -ol-3,11-dione
 -, plasma 461
 --, radioimmunoassay 461
 androstenedione
 -, blood 371
 -, plasma 371
 antibodies
 -, immobilized 337
 -, monoclonal 867, 943, 953, 959
 --, applications 867
 --, as reagents 867
 --, human 867
 --, preparation 867
 --, production 867
 --, purification 867
 --, rat 867
 -, polyclonal 867, 943, 953
 --, as reagents 867
 antigen
 -, epitopes 851
 -, factor VIII-related 15
 --, preparation 741
 --, catecholamines 741
 antigen antibody reaction 919
 antigens
 -, enzymes 943
 -, immobilized 337
 -, lymphocyte differentiation 867
 -, surface 959
 --, lymphocytes 959
 --, tissue 867
 --, kidney 867
 -, transplantation 959
 -, tumour 867
 -, urinary 867
 antirheumatics
 -, interference 559
 --, enzyme assays 559
 antisera
 -, catecholamines 741
 --, specificity 741
 α_1 -antitrypsin see also
 α_1 -proteinase inhibitor 653
 apolipoprotein A-I
 -, HDL 397
 -, laser nephelometry 113
 -, mutants 585
 apolipoprotein B
 -, laser nephelometry 113
 -, LDL 35
 apolipoprotein E
 -, laser nephelometry 113
 Arrhenius equation 851
 Arrhenius plot
 -, lipase 357
 aspartate aminotransferase
 -, assay 559
 --, drug interference 559
 -, cytosolic 723
 --, myocardial infarction 723
 ---, fibrinolysis by streptokinase 723
 -, isoenzymes 153
 --, serum 153
 ---, liver disease 153
 --, mitochondrial 723
 --, myocardial infarction 723
 ---, fibrinolysis by streptokinase 723
 -, total 723
 --, myocardial infarction 723
 ---, fibrinolysis by streptokinase 723
 assessment
 -, longitudinal 613
 --, laboratory values 613
 association reactions
 -, reversible 851
 --, physical-chemical aspects 851
 automation
 -, radioimmunoassay 883
 avidin
 -, -biotin system 953
 avidity
 -, definition 851
 Avogadro number 851
 basement membrane
 -, glomerular 223
 --, diabetes mellitus 223
 -, glycation 223
 Bayes' theorem 96
 bifunctional reagents 337
 bile acids
 -, chromatography 623
 -, faeces 623
 bilirubin
 -, neonatal 609
 --, survey 609
 bioassay
 -, analytical performance 927
 bioluminescence 337, 905
 bioluminescence assay
 -, enzymes 129
 --, nephron 129
 biotin avidin system 953
 bis(monoacylglycero)phosphate
 -, liver 199
 -, spleen 199
 bis(monoacylglycero)phospholipid
 -, liver 199
 --, Niemann-Pick's disease 199
 bis(monoacylglycero)phospholipid
 -, spleen 199
 --, Niemann-Pick's disease 199
 blastogenesis
 -, inhibition 209
 --, 17 β -carboxamide 209
 blood
 -, ammonia 105
 --, reflectometer 105
 -, CO 229
 -, CO-Hb 229
 --, constituents 301
 --, minipigs 301
 ---, reference values 301
 -, steroids 371
 --, influence of storage 371
 body functions
 -, investigation 811
 body weight
 -, loss 535
 --, marathon runner 535
 Boltzmann constant 851
 boronic acid affinity chromatography 175
 brain
 -, calmodulin 185
 breast carcinoma
 -, phosphatase, alkaline 467
 --, placental 467
 bromocresol green
 -, albumin 305, 685
 --, determination 305
 bromocresol purple
 -, albumin 685
 --, determination 685
 brush border membrane
 -, enzymes 449
 --, synthesis 449
 C-reactive protein
 -, ILSA 349
 caeruloplasmin
 -, SPALT 349
 caffeine
 -, interference 559
 --, enzyme assays 559
 calcium
 -, plasma 301, 717
 --, minipig 301
 --, physical exercise 717
 -, sweat 717
 --, physical exercise 717
 -, urine 717
 --, physical exercise 717
 calibration standard
 -, glucose 827
 calmodulin
 -, brain 185
 -, radioimmunoassay 185
 cancer
 -, colo-rectal 935
 --, identification 935
 -, prostate 331
 -, sialic acid 647
 --, serum 647
 N6-(carbamoyl-threonyl)-adenosine 175
 carbodimides 905
 carbohydrates
 -, gallstones 453
 -, gas chromatography 453
 carbon monoxide
 -, smokers 229

- carbon tetrachloride
 - , poisoning 633
 - , enzymes 633
 - , serum 633
 - , proteinase inhibitors 633
 - , serum 633
- carbonic anhydrase 159
- 17 β -carboxamide steroids
 - , blastogenesis inhibition 209
- γ -carboxyglutamic acid 123
- carboxyhaemoglobin
 - , smokers 229
- carcinoembryonic antigen 647
- carcinoma
 - , proteinase inhibitors 633
 - , serum 633
 - , thyroid 661
 - , thyroglobulin 661
 - , serum 661
- cataract
 - , formation 285
 - , by galactose 285
- catecholamines
 - , antigen preparation 741
 - , antisera 741
 - , radioimmunoassay 741
 - , plasma 539, 597
 - , and food intake 597
 - , assay 539
 - , method comparison 539
- CEA 969
- CEA antibody
 - , cell 935
 - , tumour 935
- CELIA 349, 905
- Celite 29
- cell
 - , tumour 935
 - , CEA antibody 935
 - , DNA 935
 - , volume 935
- cerebrospinal fluid
 - , 4-aminobutyric acid 379
 - , fluorimetry 379
 - , lymphocytes 483
 - , IgG synthesis 483
 - , multiple sclerosis 483
 - , non-inflammatory diseases 483
 - , procollagen type III pro-peptide 237
- checklist
 - , laboratory needs 573
 - , product features 573
- chemiluminescence 337, 905
 - , during phagocytosis 1
 - , by granulocytes 1
- chenodeoxycholic acid 623
- children
 - , alanine aminopeptidase 787
 - , urine 787
 - , reference range 787
- chloride
 - , plasma 301
 - , minipig 301
- 2-chloro-4-nitrophenol
 - , absorbance, molar lineic 489
 - , dissociation curve 489
- 2-chloro-4-nitrophenyl- β -D-malto-heptaoside
 - , substrate 489
 - , α -amylase 489
- cholesterol
 - , ester 245
 - , cleavage 245
 - , HDL 113, 397, 515
 - , LDL 35, 113, 781
 - , method comparison 781
 - , method comparison 245
 - , plasma 245, 301
 - , enzymatic determination 245
 - , multicentre study 245
 - , minipig 301
 - , serum 245
 - , enzymatic determination 245
 - , multicentre study 245
 - , VLDL 113
- cholic acid 623
- cholinesterase 671
- chromatography
 - , bile acids 623
 - , steroids 29
- chromogenic substrate 633
- cigarette smoking
 - , HDL apolipoprotein A-I 397
 - , HDL cholesterol 397
- clinical laboratory findings
 - , alcoholism 65, 79
- colipase 357
- collagen
 - , synthesis 527
 - , stimulation by platelet growth factor 527
- colo-rectal cancer
 - , cells 935
 - , identification 935
- constituent
 - , combination 791
- contrast media
 - , X-ray 787
 - , and alanine amino-peptidase excretion 787
- coronary heart disease
 - , risk factors 515, 591
- cortisol
 - , blood 371
 - , free 371
 - , blood 371
 - , plasma 371
 - , plasma 371 597, 717
 - , daily periodicity 597
 - , and food intake 597
 - , physical exercise 717
 - , SPALT 349
- costs
 - , analysis 927
- creatine kinase
 - , assay 559
 - , drug interference 559
 - , isoenzyme MB 603, 723, 751
 - , and serum matrix 751
 - , method comparison 603, 751
 - , myocardial infarction 603, 723
 - , fibrinolysis by streptokinase 723
 - , myocardial infarction 723
 - , fibrinolysis by streptokinase 723
- creatinine
 - , myocardial infarction 723
 - , fibrinolysis by streptokinase 723
- creatinine
 - , plasma 301
 - , minipig 301
 - , urine 731
 - , and food composition 731
- critical difference 613
- curve fitting
 - , enzyme immunoassay 895
- cytidine
 - , assay 175
- cytological regeneration test 505
- daily periodicity
 - , cortisol 597
 - , evaluation 319
 - , multivariate 319
 - , processing 407
 - , electrophoresis 407
- decision making 791
- definitive method
 - , oestradiol-17 β 551
- dehydroepiandrosterone sul-fate
 - , blood 371
 - , plasma 371
- density, mass
 - , urine 419
- deoxycholic acid 623
- detection limits
 - , analytical methods 927
- diabetes mellitus
 - , albumin 47
 - , glycated 47
 - , basement membrane 223
 - , glomerular 223
 - , haemoglobin 47
 - , glycated 47
 - , hyperglycaemia 21
 - , and glycosidases 21
 - , kidney 21
 - , urine 21
 - , nephropathy 21
 - , proteinase inhibitors 633
 - , serum 633
 - , therapy control 47
- diagnostic efficiency 79
- diagnostic performance
 - , tumour markers 969
- diagnostic reagents sets
 - , evaluation 573
 - , performance, analytical 573
 - , practicability 573
 - , selection 573
- diagnostic sensitivity 79
- diagnostic specificity 79
- diagnostic test criteria 969
- diagnostic value
 - , haptoglobin typing 109
- diazoisoluminol 905
- dibucaine number 671
- S-(1,2-dicarboxyethyl)-L-cysteine
 - , lens 285
- S-(1,2-dicarboxyethyl)gluta-thione
 - , lens 285
- 3,4-dichlorophenylethylamine
 - , antigen preparation 741
- diclofenac
 - , interference 559
 - , enzyme assays 559
- difference
 - , critical 613
- dioxin
 - , enzyme immunoassay 759
 - , interference 759
 - , by immunoglobulins 759
 - , by rheumatoid factors 759
 - , serum 119
 - , radioimmunoassay 119
 - , urine 403
 - , radioimmunoassay 403
- dimethadione
 - , infrared spectrometry 641
- 3,4-dimethoxyphenylethyl-amine
 - , radioimmunoassay 741
- N6-dimethyladenosine
 - , assay 175
- N2-dimethylglanosine
 - , assay 175
- discrimination
 - , between two populations 791
 - , by multivariate decision limits 791
- dissociation curve
 - , 2-chloro-4-nitrophenol 489
 - , 4-nitrophenol 489
- distribution free methods
 - , data evaluation 319
- DNA
 - , cell 935
 - , tumour 935
- dopamine
 - , antigen preparation 741
 - , plasma 597
 - , radioimmunoassay 741
- drug
 - , effects 271, 275
 - , in clinical chemistry 271, 275
 - , monitoring 271
- drug interference 559
- duration
 - , analysis 927
- ECIA 895
- education
 - , technicians 497
- EEIA 895
- efficiency
 - , diagnostic 79, 229
- EIA 905
- Ekins equation 851, 883
- elastase
 - , leukocytes 693
 - , α_1 -proteinase inhibitor complex 693
- electrolytes
 - , physical exercise 717
- electrophoresis see also gel electrophoresis 253
 - , interpretation, computer assisted 407
 - , two dimensional 53
 - , clinical application 53
 - , paraproteins 53
 - , characterization 53
- ELISA 895
- EMIT 895
- EMMIA 895

- enteropeptidase
 -, brush-border membrane 449
- enzyme
 -, assays 559
 ---, interference 559
 ---, by drugs 559
 -, catalytic assay 943
 -, diagnostics 943
 -, immunoabsorption 943
 -, immunoassay 559, 693, 759, 895, 943
 ---, application 895
 ---, competitive 895
 ---, coupling procedures 895
 ---, curve fitting 895
 ---, digoxin 759
 ---, interference 759
 ---, by immunoglobulins 759
 ---, by rheumatoid factors 759
 ---, elastase- α -proteinase 693
 ---, elastase- α_1 -proteinase inhibitor complex 693
 ---, enzyme-labels 895
 ---, future trends 895
 ---, heterogeneous 895
 ---, homogeneous 895
 ---, principles 895
 -, immunoinhibition 943
 -, immunoprecipitation 943
 -, mass determination 943
 -, radioimmunoassay 943
- enzymes
 -, bioluminescence assay 129
 -, brush border membrane 449
 ---, synthesis 449
 -, label 895
 ---, immunoassay 895
 -, plasma 97
 ---, rat 97
 -, urine 523
- epinephrine
 -, plasma 597
- ERMA 895
- erythrocytes
 -, adenyl cyclase 281
 -, magnesium 717
 -, membrane protein 281
 ---, abnormalities 281
 ---, pseudohypoparathyroidism type 1 281
 -, zinc 159
- evaluation
 -, diagnostic reagent sets 573
 ---, interference 275
 ---, by drugs 275
 -, kits 817, 827
 -, longitudinal 613
 ---, laboratory values 613
 -, multivariate 319
 ---, data 319
 -, performance 817, 827
 -, reference ranges 319
- exercise
 -, physical 717
 ---, Mg supplementation 717
 ---, aldosterone 717
 ---, cortisol 717
 ---, electrolytes 717
- extraction
 -, parathyrin 479
- factor VIII-related antigen
 -, plasma 15
 ---, acute liver failure 15
 ---, liver cirrhosis 15
- faeces
 -, bile acids 623
- ferritin
 -, ILMA 349
- fibrinolysis
 -, acute myocardial infarction 723
 ---, by streptokinase 723
 ---, biochemical parameters 723
- fibronectin
 -, plasma 15
 ---, acute liver failure 15
 ---, liver cirrhosis 15
- flecainid
 -, plasma 389
 ---, HPLC 389
- flow-cytometry 935
- fluorimetry
 -, 4-aminobutyric acid 379
 ---, cerebrospinal fluid 379
 -, enzymes 189
- foetal development
 -, magnesium 473
- α_1 -foetoprotein 905
- follow-up
 -, thyroid cancer 661
- food
 -, composition 731
 ---, creatinine 731
 ---, urine 731
 ---, 3-methylhistidine 731
 ---, urine 731
 -, intake 597
 ---, and catecholamines 597
 ---, and cortisol 597
 ---, and glucose 597
 ---, and insulin 597
- function tests
 -, testing pharmaceuticals 811
- galactose
 -, cataract formation 285
- β -galactosidase
 -, kidney 21
 ---, diabetes mellitus 21
 -, liver 735
 ---, isolation 735
 ---, specificity 735
 -, urine 21
 ---, diabetes mellitus 21
- gallstones
 -, carbohydrates 453
 -, glycoproteins 453
- gammopathy
 -, monoclonal 253
- gas chromatography
 -, carbohydrates 453
 ---, gallstones 453
 -, costs 927
 -, duration 927
 -, hormones 927
 ---, analytical performance 927
 -, pharmaceuticals 927
 ---, analytical performance 927
 -, phenytoin 773
 -, toxicology 699
- Gc-globulin
 -, isoelectric focusing 545
 -, phenotyping 545
- gel electrophoresis
 -, two dimensional 253
- genetic variants
 -, pseudocholinesterase 671
- gentamycin 905
- Gibbs-Helmholtz* equation 851
- Gibbs potentials
 -, immunoreactions 851
- glomerulonephritis
 -, enzymes 523
 ---, urine 523
- glucocorticoids
 -, receptors 209
- gluconeogenesis
 -, marathon runner 535
- glucose
 -, assay 827
 ---, interferences 827
 -, calibration standard 827
 -, method evaluation 827
 -, plasma 301
 ---, minipig 301
 -, serum 597
 ---, and food intake 597
- glucose-6-phosphate dehydrogenase
 -, bioluminescence assay 129
- α -glucosidase
 -, kidney 21
 ---, diabetes mellitus 21
 -, urine 21
 ---, diabetes mellitus 21
- glutamate dehydrogenase 153
- , myocardial infarction 723
 ---, fibrinolysis by streptokinase 723
- γ -glutamyltransferase
 -, brush border membrane 449
 -, urine 523
- γ -glutamyltranspeptidase 153
- glycation
 -, albumin 223
 -, basement membrane 223
 -, proteins 47
- glycerolphosphate oxidase
 -, triglyceride assay 165
- glycodeoxycholic acid 623
- glycoproteins
 -, enzymatic degradation 735
 -, gallstones 453
- glycosaminoglycans
 -, synthesis 527
 ---, stimulation by platelet growth factor 527
- granulocytes
 -, elastase 693
 -, function 1
 -, isolation 1
 -, leukocytes 693
 ---, polymorphonuclear 693
 ---, elastase 693
 -, phagocytosis 1
 ---, and chemiluminescence 1
- Greiner analyser G 300
 -, urea 195
- growth stimulating factor
 -, platelets 527
 ---, isolation 527
- guanosine
 -, assay 175
- haematocrit
 -, blood 301
 ---, minipig 301
- haematology
 -, testing pharmaceuticals 811
- haemodialysis
 -, oxalic acid 261
- haemoglobin
 -, glycolated 47
- haemolytic disease
 -, haptoglobin 109
- haptens
 -, protein conjugates 337
- haptoglobin
 -, phenotyping 109
 ---, diagnostic value 109
- HDL
 -, apolipoprotein A-I 397
 -, cholesterol 113, 397, 515
 -, composition 141
 -, phosphatidyl choline 515
 ---, and risk factors of coronary heart disease 515
- hepatitis
 -, fulminant 291
 ---, tryptophan, free 291
 ---, plasma 291
- hepatotoxicity
 -, valproic acid 309
 ---, metabolites 309
- heteroscedasticity 319
- high performance liquid chromatography see also HPLC
- , flecainid 389
 -, thiopental 385
- histocompatibility
 -, testing 959
- Hitachi 705
 -, amyloses 41
- homocarnosine 379
- hormones
 -, bioassay 927
 -, gas chromatography 927
 -, HPLC 927
 -, immunoassay 927
- hospitalisation
 -, influence 613
 ---, on laboratory values 613
- HPLC
 -, hormones 927
 -, pharmaceuticals 927
 -, ribonucleosides 175
 ---, minor 175
- hybridoma technology 867
- hydroperoxides
 -, organic 711
 ---, lung lavage fluid 711
- α -hydroxybutyrate dehydrogenase
 -, assay 559
 ---, drug interference 559
 -, myocardial infarction 723
 ---, fibrinolysis by streptokinase 723
- 3-hydroxybutyrate dehydrogenase
 -, bioluminescence assay 129
- hydroxymethylfurfural 47
- 17-hydroxyprogesterone
 -, blood 371
 -, plasma 371
- hydroxyproline
 -, total 123
 ---, serum 123

- hyperglycaemia
 -, rat 21
- hyperlipaemia
 -, lipoprotein composition 141
- hyperparathyroidism
 -, analyte pattern 319
- ibuprofen
 -, interference 559
 --, enzyme assays 559
- IgG
 -, synthesis 483
 --, by lymphocytes 483
 ---, cerebrospinal fluid 483
 ----, multiple sclerosis 483
 ----, non-inflammatory diseases 483
- ILMA 349, 905
- ILSA 349, 905
- immunoabsorption
 -, enzymes 943
- immunoassay
 -, costs 927
 -, duration 927
 -, enzyme- 895
 -, enzymes 943
 -, hormones 927
 --, analytical performance 927
 -, luminescence 337, 349, 905
 -, macro solid phase 349
 -, particle counting 919
 -, peptides 927
 --, analytical performance 927
 -, pharmaceuticals 927
 --, analytical performance 927
 -, phenytoin 773
 -, phosphatase, alkaline, placental 467
 -, proteins 927
 analytical performance 927
 -, radio- 883
 -, solid phase 337
- immunodiffusion
 -, radial 109, 919
 --, haptoglobin 109
- immuno-enzymometric assay 895
- immunoglobulins
 -, interference 759
 --, digoxin assay 759
- immunohistochemistry
 -, procedures 953
- immunoinhibition
 -, enzymes 943
- immunonephelometry
 -, α_2 -macroglobulin 633
 -, α_1 -proteinase inhibitor 633
- immunoprecipitation
 -, enzymes 943
- indometacin
 -, interference 559
 --, enzyme assays 559
- infarction
 -, acute myocardial 723
 --, fibrinolysis by streptokinase 723
 ---, biochemical parameters 723
- inflammatory diseases
 -, sialic acid 647
 --, serum 647
- influence factor
 -, biological 65
 --, alcohol 65
- influences
 -, on laboratory values 613
 --, age 613
 --, hospitalisation 613
 --, sex 613
- infrared spectrometry
 -, dimethadione 641
 -, trimethadione 641
- inhibitor
 -, blastogenesis 209
 --, 17β -carboxamide steroids 209
 -, proteinase 633, 653
 -, α_1 -proteinase 693
- inosine
 -, assay 175
- instrumentation
 -, toxicology 699
- insulin
 -, serum 597
 --, and food intake 597
- interconversion
 -, 3-oxo-5 α -steroid Δ^4 -oxidoreductase 705
 --, liver 705
 ---, rat 705
- interferences 817
 -, α -amylase assay 489, 677
 -, analgesics 559
 --, enzyme assays 559
 -, analytical 271, 275
 --, evaluation 275
 -, antirheumatics 559
 --, enzyme assays 559
 -, glucose assay 827
 -, immunoglobulins 759
 --, enzyme immunoassay 759
 ---, digoxin 759
 -, ions 419
 --, SG test strip 419
 -, rheumatoid factors 759
 --, enzyme immunoassay 759
 ---, digoxin 759
 -, triglyceride assay 165
 -, uraemia 773
 --, phenytoin assay 773
- interpretation
 -, computer assisted 407
 --, electrophoresis 407
- intestine
 -, enzymes 449
 -, perfusion 449
- intracellular pH 641
- iodination
 -, thyroglobulin 661
- iotalamate
 -, and alanine aminopeptidase excretion 787
- ioxaglate
 -, and alanine aminopeptidase excretion 787
- IRMA 905
- isoamylase
 -, serum 41
 --, *p*-nitrophenyl- α -*D*-maltoheptaoside 41
- isoelectric focusing
 -, Gc-globulin 545
- isoelectric focusing
 -, vitamin D-binding protein 545
- isoenzymes
 -, α -amylase 427
 -, aspartate aminotransferase 153
 --, serum 153
 ---, liver diseases 153
 -, creatine kinase 603, 723, 751
- isoluminol 905
- isotope dilution
 -, oestradiol- 17β 551
- ketoprofen
 -, interference 559
 --, enzyme assays 559
- kidney
 -, diseases 523, 633
 --, enzymes 523
 ---, urine 523
 --, proteinase inhibitors 633
 ---, serum 633
 -, enzymes 129
 --, nephron
 -, failure 61
 --, myoglobinuric 61
 -, parathyrin extraction 479
 -, rat 21
 --, glycosidases 21
 ---, diabetes mellitus 21
 -, transplants 523
 --, enzymes 523
 ---, urine 523
- Kirchhoff* equation 851
- kits
 -, diagnostic 817, 827
 --, evaluation 817, 827
- Kupffer* cells 219
- kurtosis
 -, definition 97
- labelling
 -, reagent package 573
- laboratory values
 -, assessment 613
 -, evaluation 613
 -, variations 613
- lactate dehydrogenase
 -, assay 559
 --, drug interference 559
 -, myocardial infarction 723
 --, fibrinolysis by streptokinase 723
- laser nephelometry
 -, apolipoproteins 113
- lavage fluid
 -, lung 711
 --, hydroperoxides, organic 711
- lens
 -, S-(1,2-dicarboxyethyl)L-cysteine 285
 -, S-(1,2-dicarboxyethyl)-glutathione 285
- leukocytes
 -, neuraminidase 189
 -, polymorphonuclear 693
 --, elastase 693
 -, sialidase 189
- LDL
 -, apolipoprotein B 35
 -, cholesterol 35, 113, 781
 --, method comparison 781
- LDL
 -, composition 141
 -, precipitation 781
 --, by sulphopolyanions 781
- ligand binding assay
 -, duration 927
 -, fundamental analytical steps 927
- light scattering 919
- likelihood quotient 229
- linear regression 431
- lipase
 -, serum 357
 --, titrimetric assay 357
 ---, effect of temperature 357
- lipids
 -, *Niemann-Pick's* disease 199
 -, peroxidation 711
- lipoprotein (a) 591
- lipoproteins see also HDL, LDL, VLDL
 -, constituents 35
 -, fractions 141
 --, composition 141
 ---, in health 141
 ---, in hyperlipaemics 141
 -, serum 113
 --, constituents 113
- lithocholic acid 623
- liver
 -, acute failure 15
 --, factor VIII-related antigen 15
 ---, plasma 15
 --, fibronectin 15
 ---, plasma 15
 -, cirrhosis 15, 147, 291, 319
 --, analyte pattern 319
 --, factor VIII-related antigen 15
 ---, plasma 15
 --, fibronectin 15
 ---, plasma 15
 --, β_2 -microglobulin 147
 ---, plasma 147
 ---, production 147
 --, tryptophan, free 291
 ---, plasma 291
 -, diseases 153, 633
 --, aspartate aminotransferase 153
 ---, isoenzymes 153
 ----, serum 153
 --, proteinase inhibitors 633
 ---, liver 633
 -, β -galactosidase 735
 --, isolation 735
 --, specificity 735
 -, lipids 199
 --, *Niemann-Pick's* disease 199
 -, parathyrin extraction 479
 -, rat 705
 --, 3-oxo-5 α -steroid Δ^4 -oxidoreductase 705
 ---, interconversion 705
- Loewe, Walter Siegfried* (1884-1963) 505
- longitudinal evaluation
 -, laboratory values 613
- long term study
 -, plasma constituents 97
 --, rat 97

- Lp(a) 591
luciferase 129
lucigenin I
luminescence 337, 349
-, immunoassay 905
-, measurement 905
luminol 1, 337, 905
luminometers 905
lung
-, alveolar surfactant 711
-, lavage fluid 711
---, hydroperoxides, organic 711
lymphocytes
-, blastogenesis 209
-, cerebrospinal fluid 483
---, IgG synthesis 483
---, multiple sclerosis 483
---, non-inflammatory diseases 483
-, differentiation 867
---, antigens 867
-, surface antigens 959
lysophosphatidylcholine
-, liver 199
-, spleen 199
lysophosphatidylethanolamine
-, liver 199
---, spleen 199
- α_2 -macroglobulin
-, assay 633
---, serum 633
-, multiple sclerosis 653
macrophage 219
magnesium
-, erythrocytes 717
-, physical exercise 717
-, foetal development 473
-, metabolism 473
-, plasma 301, 717
---, minipig 301
---, physical exercise 717
-, supplementation 717
---, in physical exercise 717
---, and cortisol 717
---, and electrolytes 717
---, sweat 717
---, physical exercise 717
-, urine 717
---, physical exercise 717
marathon runner
-, amino acid metabolism 535
-, gluconeogenesis 535
marker
-, tumour 969
mass density
-, urine 419
mass spectra
-, valproic acid 309
---, metabolites 309
mass spectrometry
-, oestradiol-17 β 551
-, toxicology 699
matrix
-, influence 305
---, albumin assay 305
---, by bromocresol green 305
-, serum 751
---, creatine kinase MB 751
measles
-, antibodies 653
---, multiple sclerosis 653
- membrane
-, protein 281
---, abnormality 281
metabolism
-, magnesium 473
-, parathyrin 479
-, valproic acid 309
metanephrine
-, radioimmunoassay 741
metastases
-, diagnosis 969
method comparison
-, α -amylase 677
-, catecholamines 539
-, cholesterol 245
---, LDL 781
-, creatine kinase MB 603, 751
-, phenytoin 773
-, regression procedures 431
-, statistical problems 265
method evaluation
-, glucose 827
methods
-, recommended 811
---, testing pharmaceuticals 811
3-methoxy-4-hydroxyphenyl-ethyleneglycol 741
-, radioimmunoassay 741
3-methoxytyramine
-, radioimmunoassay 741
N1-methyladenosine
-, assay 175
N6-methyladenosine
-, assay 175
3-O-methyldopamine
-, antigen preparation 741
N1-methylguanosine
-, assay 175
N2-methylguanosine
-, assay 175
3-methylhistidine
-, meat 731
-, urine 731
---, and food composition 731
N1-methylinosine
-, assay 175
methyl palmitate
-, reticuloendothelial depression 219
methylumbelliferyl-N-acetylneuraminic acid 189
Michaelis constant
-, β -galactosidase 735
---, liver 735
microdissection
-, nephron 129
 β_2 -microglobulin
-, plasma 147
---, liver cirrhosis 147
-, production 147
---, liver cirrhosis 147
minerals
-, plasma 97
---, rat 97
minipig
-, blood constituents 301
---, reference values 301
mitogenesis test 505
model reactions
-, monovalent 851
-, polyvalent 851
molar lineic absorbance see also absorbance 489
- monitoring
-, drug 271
-, tumour 969
multicentre study
-, α -amylase 677
-, cholesterol 245
multiple sclerosis
-, α_2 -macroglobulin 653
-, measles antibodies 653
-, plasminogen 653
-, proteinase inhibitors 653
-, IgG synthesis 483
---, by lymphocytes 483
---, cerebrospinal fluid 483
Multistix SG 419
multivariate decision limits
-, discrimination of populations 791
mutants
-, apolipoprotein A-I 585
myocardial infarction 723
-, creatine kinase-MB 603
-, proteinase inhibitors 633
---, serum 633
myoglobin
-, myocardial infarction 723
---, fibrinolysis by streptokinase 723
-, urine 61
radioimmunoassay 61
- nandrolone
-, plasma 29
---, radioimmunoassay 29
-, serum 29
---, radioimmunoassay 29
nephelometric inhibition method 919
nephelometry 919
nephron
-, enzymes 129
-, microdissection 129
nephropathy
-, diabetic 21
---, rat 21
nephrotoxicity
-, contrast media 787
---, and alanine aminopeptidase excretion 787
neuraminidase
-, leukocytes 189
newborns
-, bilirubin 609
Niemann-Pick's disease
-, lipids 199
4-nitrophenol
-, dissociation curve 489

-nitrophenylheptaoside
-, substrate 677
---, α -amylase 677

-nitrophenyl-maltoheptaoside
-, α -amylase substrate 427
non-inflammatory CNS diseases
-, IgG synthesis 483
---, by lymphocytes 483
---, cerebrospinal fluid 483
non-parametric analysis 265
noradrenaline 539
norepinephrine
-, plasma 597
normetanephrine
-, radioimmunoassay 741

nortestosterone
-, plasma 29
---, radioimmunoassay 29
-, serum 29
---, radioimmunoassay 29

oestradiol
-, blood 371
-, plasma 371
oestradiol-17 β
-, definitive method 551
-, isotope dilution 551
-, mass spectrometry 551
oestrogens
-, detection methods 505
-, in plants 505
oestrone
-, blood 371
-, plasma 371
opsonization 1
ornithine carbamyltransferase 153
osmolality
-, urine 419
---, test strip 419
osmolarity
-, plasma 301
---, minipig 301
oxalic acid
-, haemodialysis 261
-, plasma 261
oxidase
-, glycerolphosphate 165
3-oxo-5 α -steroid Δ^4 -oxidoreductase 705
-, interconversion 705
-, liver 705
---, rat 705
11-oxotestosterone
-, plasma 461
---, radioimmunoassay 461
oxygen
-, reduction 1
---, during phagocytosis 1

PACIA 919
Pager's disease
-, hydroxyproline 123
---, serum 123
parameter
-, combination 791
paraproteins
-, serum 53
---, characterization 53
parathyrin
-, carboxylterminal 479
---, radioimmunoassay 479
-, metabolism 479
particle counting immunoassay 919
pCO
-, blood 301
---, minipig 301
peptides
-, immunoassay 927
performance
-, analytical 573, 817, 827
---, diagnostic reagent sets 573
---, evaluation 817, 827
perfusion
-, intestine 449
peroxidation
-, lipids 711

- peroxides
 -, lung lavage fluid 711
 PGLIA 895
 pH
 -, blood 301
 --, minipig 301
 -, intracellular 641
 pH-stat method
 -, adenosine deaminase 769
 -, principle 769
 phagocytosis
 -, by granulocytes 1
 --, chemiluminescence 1
 pharmaceuticals
 -, gas chromatography 927
 -, HPLC 927
 -, immunoassay 927
 -, testing 811
 --, clinical chemical tests 811
 phenacetin
 -, interference 559
 --, enzyme assays 559
 phenobarbital
 -, interference 559
 --, enzyme assays 559
 phenotyping
 -, Gc-globulin 545
 -, haptoglobin 109
 -, vitamin D-binding protein 545
 phenytoin
 -, gas chromatography 773
 -, immunoassay 773
 -, interference 773
 --, uraemia 773
 -, method comparison 773
 phosphatase
 -, acid 331
 --, serum 331
 -, alkaline 449, 467, 523, 559
 --, assay 559
 ---, drug interference 559
 --, brush border membrane 449
 --, placental 467
 ---, serum 467
 ---, tumour tissue 467
 --, urine 523
 phosphate, inorganic
 -, plasma 301
 --, minipig 301
 phosphatidyl choline
 -, HDL 515
 --, and risk factors of coronary heart disease 515
 -, liver 199
 -, lysosomes 199
 -, spleen 199
 phosphatidylethanolamine
 -, liver 199
 -, lysosomes 199
 -, spleen 199
 phosphatidylinositol
 -, liver 199
 -, lysosomes 199
 -, spleen 199
 phosphatidylserine
 -, liver 199
 -, lysosomes 199
 -, spleen 199
 phospholipids
 -, liver 199
 --, *Niemann-Pick's* disease 199
 phospholipids
 -, spleen 199
 --, *Niemann-Pick's* disease 199
 phosphorescence 905
 phosphotungstic acid 35
 Planck effectivity quantum 851
 plants
 -, oestrogens 505
 plasma
 -, aldosterone 717
 --, physical exercise 717
 -, analytes 723
 --, myocardial infarction 723
 ---, fibrinolysis by streptokinase 723
 -, calcium 717
 --, physical exercise 717
 -, catecholamines 539, 597
 --, method comparison 539
 -, cholesterol 245
 -, constituents 97, 301
 --, minipigs 301
 ---, reference values 301
 --, variance 97
 ---, rat 97
 -, cortisol 597, 717
 --, physical exercise 717
 -, dopamine 597
 -, enzymes 723
 --, myocardial infarction 723
 ---, fibrinolysis by streptokinase 723
 -, epinephrine 597
 -, factor VIII-related antigen 15
 --, acute liver failure 15
 --, liver cirrhosis 15
 -, fibronectin 15
 --, acute liver failure 15
 --, liver cirrhosis 15
 -, flecainid 389
 --, HPLC 389
 -, magnesium 717
 --, physical exercise 717
 -, proteinase inhibitors 653
 -, β_2 -microglobulin 147
 --, liver cirrhosis 147
 -, nandrolone 29
 --, radioimmunoassay 29
 -, norepinephrine 597
 -, nortestosterone 29
 --, radioimmunoassay 29
 -, oxalic acid 261
 --, 11-oxotestosterone 461
 --, radioimmunoassay 461
 -, potassium 717
 --, physical exercise 717
 -, proteinase inhibitors 653
 -, proteins, total 653
 -, sodium 717
 --, physical exercise 717
 --, steroids 371
 --, influence of storage 371
 -, tryptophan, free 291
 --, hepatitis, fulminant 291
 --, liver cirrhosis 291
 -, valproic acid 309
 --, metabolites 309
 plasminogen
 -, multiple sclerosis 653
 platelets
 -, growth stimulating factor 527
 -, growth stimulating factor 527
 -, isolation 527
 PMN-elastase
 -, assay 693
 potassium
 -, plasma 301, 717
 --, minipig 301
 --, physical exercise 717
 -, sweat 717
 --, physical exercise 717
 -, urine 717
 --, physical exercise 717
 practicability
 -, diagnostic reagent sets 573
 precision
 -, radioimmunoassay 883
 predictive value 229
 -, tumour markers 969
 principal compound procedures 431
 probability theory 791
 procollagen type III
 -, propeptide 237
 --, aminoterminal 237
 ---, CSF 237
 product information 573
 production
 -, β_2 -microglobulin 147
 --, liver cirrhosis 147
 -, reference values 203
 prognosis
 -, tumour 969
 prostate
 -, cancer 331
 protein
 -, abnormal 281
 --, erythrocyte membrane 281
 ---, pseudohypoparathyroidism type 1 281
 -, immunoassay 927
 -, mapping 253
 --, total 301, 653
 --, plasma 301
 ---, minipig 301
 ---, multiple sclerosis 653
 protein kinase 705
 proteins
 -, electrophoresis 407
 --, interpretation, computer assisted 407
 -, silver staining 53
 proteinase inhibitor
 -, multiple sclerosis 653
 α_1 -proteinase inhibitor
 -, assay 633
 --, serum 633
 --, elastase complex 693
 -, multiple sclerosis 653
 pseudocholinesterase
 -, genetic variants 671
 -, serum 671
 --, continuous colorimetric assay 671
 pseudohypoparathyroidism
 -, type 1 281
 --, protein abnormality 281
 ---, erythrocyte membrane 281
 pseudouridine
 -, assay 175
 pyelonephritis
 -, enzymes 523
 --, urine 523
 quality
 -, analytical 883
 radial immunodiffusion 919
 radioimmunoassay
 -, application 883
 -, automatization 883
 -, calmodulin 185
 -, catecholamines 741
 -, detection limit 883
 -, developmental trends 883
 -, digoxin 119, 403
 --, urine 403
 -, enzymes 943
 -, history 883
 -, instrumentation 883
 -, myoglobin 61
 -, nandrolone 29
 -, nortestosterone 29
 -, 11-oxotestosterone 461
 -, parathyrin 479
 --, carboxylterminal 479
 -, principles 883
 -, propeptide 237
 --, procollagen type III 237
 -, quality, analytical 883
 -, reliability 883
 -, sensitivity 61
 --, definition 61
 -, separation methods 883
 -, substances assayable 883
 -, thyroglobulin 661
 rat
 -, diabetes mellitus 21
 -, liver 705
 --, 3-oxo-5 α -steroid Δ^4 -oxidoreductase 705
 ---, interconversion 705
 --, plasma constituents 97
 reaction
 -, energies 851
 -, model 851
 --, monovalent 851
 --, polyvalent 851
 reaction kinetics 851
 reaction rate constants 851
 reactive equilibrium constants 851
 reagent plate
 -, ammonia 105
 reagent sets 817, 827
 receiver operating characteristic analysis 229
 receptors
 -, glucocorticoid 209
 reference interval
 -, analytes 65
 -, appropriate use 613
 reference materials 573, 817, 827
 reference range
 -, alanine aminopeptidase 787
 --, urine 787
 ---, children 787
 -, blood constituents 301
 -, children 301
 -, elastase 693
 -, evaluation 319
 reference values
 -, blood constituents 301
 --, minipig 301
 -, production 203
 reflectometer
 -, blood ammonia 105

- regression analysis 265
- regression procedures
 - , method comparison 431
- reliability
 - , radioimmunoassay 883
- renal disease
 - , proteinase inhibitors 633
 - , serum 633
- rheumatoid factors
 - , interference 759
 - , digoxin assay 759
- RIA 905
- ribonucleosides
 - , minor 175
 - , HPLC assay 175
 - , serum 175
 - , urine 175
- risk factors
 - , coronary heart disease 515, 591
- sample size
 - , determination 431
- sandwich assay 895
- Scatchard plot 883
- screening
 - , tumour 969
- selection
 - , diagnostic reagent sets 573
 - , individuals 203
 - , for reference values 203
- sensitivity
 - , diagnostic 79, 229, 969
 - , tumour markers 969
 - , radioimmunoassay 61
 - , definition 61
- serum
 - , albumin 305, 685
 - , bromocresol green 305
 - , bromocresol purple 685
 - , amylase 41
 - , *p*-nitrophenyl- α -*D*-maltoheptaoside 41
 - , α -amylase 427, 489, 677
 - , 2-chloro-4-nitrophenyl- β -*D*-maltoheptaoside 489
 - , *p*-nitrophenyl-maltoheptaoside 427
 - , action pattern 427
 - , aspartate aminotransferase 153
 - , isoenzymes 153
 - , liver diseases 153
 - , cholesterol 245
 - , constituents 811
 - , testing pharmaceuticals 811
 - , digoxin 119
 - , radioimmunoassay 119
 - , enzymes 559
 - , interferences 559
 - , glucose 597
 - , HDL apolipoprotein A–1 397
 - , HDL cholesterol 397
 - , hydroxyproline 123
 - , total 123
 - , insulin 597
 - , isoamylase 41
 - , *p*-nitrophenyl- α -*D*-maltoheptaoside 41
 - , lipase 357
 - , titrimetric assay 357
 - , effect of temperature 357
- serum
 - , lipoproteins 113
 - , constituents 113
 - , α_2 -macroglobulin 633
 - , matrix 751
 - , creatine kinase MB 751
 - , nandrolone 29
 - , radioimmunoassay 29
 - , nortestosterone 29
 - , radioimmunoassay 29
 - , paraproteins 53
 - , characterization 53
 - , phenytoin 773
 - , gas chromatography 773
 - , immunoassay 773
 - , phosphatase 331, 467
 - , acid 331
 - , alkaline 467
 - , placental 467
 - , proteinase inhibitor 653
 - , α_1 -proteinase inhibitor 633
 - , pseudocholinesterase 671
 - , ribonucleosides 175
 - , minor 175
 - , HPLC assay 175
 - , sialic acid 647
 - , cancer 647
 - , inflammatory diseases 647
 - , thiopental 385
 - , HPLC 385
 - , thyroglobulin 661
 - , thyroid carcinoma 661
 - , triglycerides 165
 - , VLDL 35
 - , precipitation 35
- sex dependence
 - , laboratory values 613
- sex hormones 505
- sex hormones binding globulin 371
- SG test strip 419
- sialic acid
 - , serum 647
 - , cancer 647
 - , inflammatory diseases 647
- sialidase
 - , leukocytes 189
- sialidosis 189
- silver staining
 - , proteins 53, 253
- Sips-Hill-Nerst equation 851
- skewness
 - , definition 97
- smokers
 - , carboxyhaemoglobin 229
 - , CO 229
- sodium
 - , plasma 301, 717
 - , minipig 301
 - , physical exercise 717
 - , sweat 717
 - , physical exercise 717
 - , urine 717
 - , physical exercise 717
- solid phase immunoassay 337 349
- Southern blot 394
- SPALT 349, 905
- specificity
 - , diagnostic 79, 229, 969
 - , tumour markers 969
- spectrometers
 - , specifications 565
 - , listing 565
- sphingomyelin
 - , liver 199
 - , spleen 199
- spleen
 - , lipids 199
 - , Niemann-Pick's disease 199
- staging
 - , tumour 969
- standardisation
 - , glucose 827
- standard bicarbonate
 - , blood 301
 - , minipig 301
- standardisation
 - , albumin 685
 - , bromocresol purple 685
- standardised principal components analysis 265
- statistics
 - , problems 265
 - , in method comparisons 265
- steroids
 - , blood 371
 - , influence of storage 371
 - , chromatography 29
 - , plasma 371
 - , influence of storage 371
- stomach carcinoma
 - , phosphatase, alkaline 467
 - , placental 467
- storage
 - , blood 371
 - , steroid assay 371
 - , plasma 371
 - , steroid assay 371
- streptokinase
 - , fibrinolysis 723
 - , in myocardial infarction 723
 - , biochemical parameters 723
- streptozotocin 21
- substrate
 - , chromogenic 633
- 3 α -sulfolithocholic acid 623
- surfactant
 - , alveolar 711
 - , hydroperoxides, organic 711
- survey
 - , bilirubin 609
 - , neonatal 609
- sweat
 - , calcium 717
 - , physical exercise 717
 - , magnesium 717
 - , physical exercise 717
 - , potassium 717
 - , physical exercise 717
 - , sodium 717
 - , physical exercise 717
- SWFIA 895
- synephrine
 - , radioimmunoassay 741
- T cell
 - , monitoring 959
 - , monoclonal antibodies 959
 - , subsets 959
- taurocholic acid 623
- technicians
 - , education 497
 - , training 497
- temperature
 - , dependence 357
 - , lipase assay 357
- test strip
 - , osmolality 419
 - , urine 419
- testosterone
 - , blood 371
 - , free 371
 - , blood 371
 - , plasma 371
 - , plasma 371
- therapy
 - , control 47
 - , diabetes mellitus 47
 - , monitoring 215
 - , thyroid carcinoma 215
- thermodynamic functions 851
- thiopental
 - , serum 385
 - , HPLC 385
- β -thromboglobulin 527
- thyroglobulin
 - , serum 661
 - , thyroid carcinoma 661
 - , therapy monitoring 215
 - , thyroid carcinoma 215
- thyroid
 - , carcinoma 215, 661
 - , therapy monitoring 215
 - , thyroglobulin 215, 661
 - , serum 661
- thyroxine
 - , SPALT 349
- thyroxine binding globulin
 - , CELIA 349
- tissue
 - , antigens 867
 - , typing 959
- titrimetric assay
 - , lipase 357
 - , effect of temperature 357
- toxicology
 - , instrumentation 699
- tracer
 - , luminescent 337
- training
 - , technicians 497
- transformation
 - , Langmuir-Michaelis-Menten 851
 - , Scatchard 851
 - , Sips-Hill-Nerst 851
- transplantation
 - , antigens 959
- trauma
 - , proteinase inhibitors 633
 - , serum 633
- triglycerides
 - , hydrolysis 357
 - , by lipase 357
 - , activation energy 357
 - , plasma 301
 - , minipig 301
 - , serum 165
 - , glycerolphosphate oxidase 165
 - , VLDL 113
- trimethadione
 - , infrared spectrometry 641
- tryptophan
 - , free 291
 - , plasma 291
 - , hepatitis, fulminant 291
 - , liver cirrhosis 291

- tumour
 -, antigens 867
 -, cell 935
 --, CEA antibody 935
 --, DNA 935
 --, identification 935
 --, volume 935
 -, diagnosis 969
 -, marker 647, 969
 --, diagnostic sensitivity 969
 --, diagnostic specificity 969
 --, predictive value 969
 --, sialic acid 647
 ---, serum 647
 -, monitoring 969
 -, prognosis 969
 -, screening 969
 -, staging 969
 -, tissue 467
 --, phosphatase, alkaline 467
 ---, placental 467
 turbidimetry 919
- uraemia
 -, interference 773
 --, phenytoin assay 773
- urea
 -, Greiner G 300 195
 -, myocardial infarction 723
 --, fibrinolysis by streptokinase 723
 -, plasma 301
 --, minipig 301
- uridine
 -, assay 175
- urinary antigens 867
- urine
 -, alanine aminopeptidase 787
 --, and contrast media 787
 -, α -amylase 489, 677
 --, 2-chloro-4-nitrophenyl- β -D-maltoheptaoside 489
 -, calcium 717
 --, physical exercise 717
 -, constituents 811
 --, testing pharmaceuticals 811
 -, creatinine 731
 --, and food composition 731
 -, digoxin 403
 -, enzymes 523
 --, multiple forms 523
 -, magnesium 717
 --, physical exercise 717
 -, mass density 419
 -, 3-methylhistidine 731
 --, and food composition 731
 -, myoglobin 61
 --, radioimmunoassay 61
 -, osmolality 419
 --, test strip 419
 -, potassium 717
 --, physical exercise 717
 -, rat 21
- urine
 -, rat
 --, glycosidases 21
 ---, diabetes mellitus 21
 -, ribonucleosides 175
 --, minor 175
 ---, HPLC assay 175
 -, sodium 717
 --, physical exercise 717
 -, valproic acid 309
 --, metabolites 309
 ursodeoxycholic acid 623
- validity
 -, analytic 229
 --, CO 229
 --, CO-Hb 229
 -, diagnostic 229
 --, CO 229
 --, CO-Hb 229
- valproic acid
 -, hepatotoxicity 309
 -, metabolites 309
 --, hepatotoxicity 309
 --, plasma 309
 --, urine 309
 -, plasma 309
 -, urine 309
 Q₁₀value
 -, lipase 357
 van't Hoff equation 851
 variability 817
- variance
 -, components of 97
- variations
 -, analytical 613
 -, biological 613
 -, intra-individual 613
- vitamin D-binding protein
 -, isoelectric focusing 545
 -, phenotyping 545
- VLDL
 -, cholesterol 113
 -, composition 141
 -, serum 35
 --, precipitation 35
 -, triglycerides 113
- volume
 -, cell 935
 --, tumour 935
- X-ray
 -, contrast media 787
 --, and alanine aminopeptidase excretion 787
- X-transformation 319
- zinc
 -, carbonic anhydrase 159
 -, erythrocytes 159
- zymosan
 -, reticuloendothelial stimulation 1, 219

J. Clin. Chem. Clin. Biochem.
Vol. 22, 1984, pp. 349–356

An Evaluation of Four Different Luminescence Immunoassay Systems: CELIA (chemiluminescent immunoassay), SPALT (solid-phase antigen luminescence technique), ILMA (immunoluminometric assay) and ILSA (immunoluminometric labelled second antibody)

A critical study of macro solid phases for use in immunoassay systems, Part III¹⁾

By W. G. Wood, H. Fricke, J. Haritz, A. Gadow, Heidi-Susanne Krausz, Bettina Tode, C. J. Strasburger
and P. C. Scriba

*Klinische Laboratorien, Klinik für Innere Medizin (Direktor: Prof. Dr. P. C. Scriba)
Medizinische Hochschule Lübeck*

(Received June 7/December 19, 1983)

Summary: The performance of different solid-phase luminescence immunoassays has been documented using four different assay concepts. These are CELIA (chemiluminescence immunoassay), SPALT (solid-phase antigen luminescence technique), ILMA (immunoluminometric assay) and ILSA (immunoluminometric labelled second-antibody assay). CELIA is analogous to a solid-phase radioimmunoassay and uses a labelled antigen, SPALT and ILSA use a labelled second (species-specific) antibody and ILMA a labelled substance-specific antibody, i. e. analogous to the immunoradiometric assay. Both bioluminescent and chemiluminescent labels have been used. Pyruvate kinase was used for bioluminescence and diazoluminol and N-(4-amino-butyl)-N-ethyl isoluminol hemisuccinamide for chemiluminescence. Relevant quality-control parameters and reference ranges have been given for the optimised assays. Assays described are: thyroxine, thyroxine binding globulin, cortisol, caeruloplasmin, ferritin and C-reactive protein.

Luminescence immunoassays with coefficients of variation comparable with radioimmunoassay have been designed, values of under 5% being obtainable within the working range of the assay.

Beurteilung von vier verschiedenen Lumineszenz-Immunoassays:

*CELIA (chemiluminescent immunoassay),
SPALT (solid-phase antigen luminescence technique),
ILMA (immunoluminometric assay) und
ILSA (immunoluminometric labelled second antibody).*

Eine kritische Untersuchung von Makro-Festphasen zum Gebrauch in Immunoassay-Systemen, Teil III¹⁾

Zusammenfassung: Die Entwicklung und Durchführung von Lumineszenzimmunoassays werden am Beispiel von vier verschiedenen Assaykonzepten aufgezeigt. Der CELIA (Chemilumineszenzimmunoassay) verwendet markiertes Antigen, SPALT (Solid-Phase Antigen Luminescence Technique) and ILSA (Immunoluminometric Labelled Second-Antibody Assay) markierten spezies-spezifischen „zweiten“ Antikörper und der ILMA (Immunoluminometric Assay) substanz-spezifischen Antikörper, die markiert sind. Sowohl Biolumineszenz (Pyruvatkinase)- als auch Chemilumineszenz (Diazoluminol und N-(4-Aminobutyl)-N-ethyl-isolu-

¹⁾ Part I: J. Clin. Chem. Clin. Biochem. 21, 789–787. Part II: J. Clin. Chem. Clin. Biochem. 22, 337–347.

minol-hemisuccinamid)-Markierungen wurden verwendet und gegenübergestellt. Qualitätskontrollkenngrößen und Referenzbereiche im Serum werden für die optimierten Assays ermittelt. Es werden Lumineszenzimmunoassays für die folgenden Substanzen beschrieben: Thyroxin, thyroxin-bindendes Globulin, Cortisol, Ferritin, Caeruloplasmin und C-reactives Protein.

Die entwickelten Lumineszenzimmunoassays zeigen dem Radioimmunoassay vergleichbare Variationskoeffizienten mit Werten unter 5% im relevanten Bereich.

Introduction

This third and final part of a study upon solid phases for immunoassay describes the assays which have been developed from the experiments described in the first two parts (1, 2). Both functional and non-functional assay systems have been presented as well as comparisons between different assay systems for the same analyte.

The assays described include those using labelled antigens and labelled first or second antibodies. The labels used are: diazoluminol and N-(4-aminobutyl)-N-ethyl isoluminol hemisuccinamide, the latter being coupled via an active ester of N-hydroxysuccinamide. The synthesis of the labels has already been described (2). The assays represent different analytes (haptens or peptides) and methods. Where applicable, assays which have already been introduced into the routine laboratory are presented with relevant quality-control parameters and comparisons with the methods which they have replaced.

Materials and Methods

Materials

Antibodies

Antibodies to human liver and spleen ferritins were purchased from Atlanta (Pelfreez), Heidelberg; Proma (Seward), Augsburg; Boehringer-Ingelheim (DAKO), Ingelheim; these being the distributors in the FRG. Antibodies to human C-reactive protein and human thyroxine binding globulin were obtained from Proma and Boehringer-Ingelheim.

Antibodies to caeruloplasmin were purchased from Behringwerke, Marburg a. d. L., FRG, whereas those for cortisol and thyroxine were donations from Dr. *Mario Pazzagli*, Firenze, Italy and the Fa. Henning Berlin GmbH respectively.

Donkey anti-rabbit IgG was purchased from Wellcome Diagnostika, Burgwedel, FRG and rabbit anti-sheep IgG from Boehringer Ingelheim.

Standard materials

Ferritin standards were obtained from Travenol-Clinical Assays, Munich, FRG, C-reactive protein serum standard from Behringwerke, thyroxine and cortisol standards from Henning Berlin and Diagnostic Products Corporation (Hermann Biermann, Bad Nauheim, FRG) respectively. Human transferrin was purchased from Behringwerke, human caeruloplasmin from Serva, Heidelberg, FRG or Sigma, Munich, human thyroxine binding globulin being a gift from Prof. *K. Horn* and Dr. *R. Gärtner*, Munich.

Equipment

The luminometers used were either the LKB-1251 (LKB Instruments, Gräfelfing, FRG) or the LB-950 (Laboratorium Prof. Dr. Berthold, Wildbad, FRG). The LKB-1251 was a 25-sample semi-automatic instrument with microprocessor, the LB-950 had a 300 sample capacity and was also microprocessor controlled. Both instruments were at the time of the experiments not able to process data fully so that an off-line data-processing with a desk-top computer (CBM 8032 – Commodore Business Machines, Neu-Isenburg, FRG) and spline function programme was necessary.

Methods

CELIA – chemiluminescent immunoassay

This type of assay is analogous to a solid-phase radioimmunoassay in which the first antibody was coupled to a polystyrene ball (1) and in which the tracer was an antigen labelled with N-(4-aminobutyl)-N-ethyl isoluminol hemisuccinamide instead of a radioactive marker. Table 1 shows the assay flow sheet for a TBG CELIA.

Tab. 1. Thyroxine binding globulin CELIA flow sheet.

50 µl sample or standard
200 µl assay buffer (0.05 mol/l Tris-HCl containing 2.50 g/l bovine serum albumin, pH 7.4
1 sheep anti human TBG coated ball
Incubate at ambient temperature for 30 min
50 µl diazoluminol labelled TBG (1:100 dilution*)
Incubate as above and wash with 2 × 1 ml 0.15 mol/l NaCl containing 0.15 ml/l Tween 20.
Transfer balls to measuring cuvettes and load luminometer.
The light initiation step is identical with that shown in table 2.

* The diazotisation was analogous to the method described in l. c. (2), replacing the second antibody with thyroxine binding globulin. The dilution factor given here is the further dilution of the TBG-diazoluminol. The amount of label added to each tube was approximately 100 ng.

ILMA – immunoluminometric assay

The ILMA is analogous to the IRMA (immunoradiometric assay) (3) and is especially suited for assays where the antigen is either unavailable or prohibitively expensive so that a SPALT (see below) assay is out of the question. Several antibody-pairs were tested until a suitable combination was found. Table 2 shows an assay flow sheet for a ferritin ILMA.

ILSA – immunoluminometric labelled second-antibody assay

The ILSA is identical with the ILMA, but with one exception, and that is that a labelled second antibody is used in addition to the two substance-specific antibodies used in the ILMA. This assay was only used in cases where diazoluminol was used for labelling the antibodies, in order to achieve maximal sensitivity. Table 3 shows a flow sheet for a C-reactive protein ILSA.

Tab. 2. Ferritin ILMA flow sheet.

20 µl sample or standard
 200 µl assay buffer (0.025 mol/l phosphate/0.025 mol/l Tris-HCl containing 0.5 ml/l Tween 20 and 1.25 g/l bovine serum albumin, pH 7.4)
 1 goat anti human liver ferritin coated ball
 Incubate for 3 h on a horizontal rotator (180 min⁻¹)
 Wash with 2 × 5 ml 0.15 mol/l NaCl containing 0.15 ml/l Tween 20
 200 µl N-(4-aminobutyl)-N-ethylisoluminol hemisuccinamide labelled rabbit anti human ferritin (1:500 dilution)*
 Incubate and wash as above and transfer balls to measuring cuvettes.
 Add 250 µl 0.15 mol/l NaCl and load luminometer. Initiate light reaction with 1 mol/l NaOH, 2 mg/l microperoxidase-MP 11 and 0.15 mol/l H₂O₂ (100 µl + 10 µl + 360 µl respectively). Integrate the light signal over 20 s

* This represents the dilution of the labelled antibody after coupling to N-(4-aminobutyl)-N-ethylisoluminol hemisuccinamide using the same method for labelling donkey anti rabbit IgG – see l.c. (2).

Tab. 3. C-reactive protein ILSA flow sheet.

10 µl sample or standard, 1:10 dilution in assay buffer (0.05 mol/l Tris-HCl containing 2.5 g/l bovine serum albumin, pH 7.6)
 200 µl assay buffer
 1 sheep anti human C-reactive protein coated ball
 Incubation 60 min at 37 °C in a water bath, followed by 2 × 5 ml wash with assay buffer
 200 µl rabbit anti human C-reactive protein (1:500 dilution)
 Incubate and wash as above
 300 µl diazoluminol labelled donkey anti rabbit serum (1:60 dilution*)
 Incubate as above, wash and transfer balls to measuring cuvette. Load luminometer and proceed as in table 2.

* represents the further dilution of the labelled antibody as prepared in l.c. (2).

SPALT – solid phase antigen luminescence technique

The SPALT principle has been described in detail elsewhere (4, 5), and only the variations are briefly described here. The SPALT assay can be set up as either a competitive or sequential assay, depending upon whether the solid phase antigen is added together with the first antibody and sample or after a pre-incubation of first antibody and sample. Tables 4 and 5 show competitive and sequential SPALT assays for caeruloplasmin and thyroxine respectively.

Assay semi-automation

The assays were originally set up in 55 × 12 mm polystyrene tubes which increased the time needed for pipetting and wash steps as each tube had to be processed separately. To increase throughput and reduce the workload assays were set up in either 20 or 60 well trays (cf. Abbott hepatitis kits). The wash steps were carried out using a Pentawash multiple wash device (Abbott Laboratories) where 5 wells were washed simultaneously with 5 ml wash solution. The antigen-antibody reaction was speeded up by incubating the trays on a horizontal rotator at 180 min⁻¹.

Tab. 4. Caeruloplasmin SPALT flow sheet.

50 µl sample or standard, 1:25 dilution in assay buffer (see table 2)
 150 µl rabbit anti caeruloplasmin (1:500 dilution)
 Incubate at ambient temperature for 10 min*
 1 human caeruloplasmin coated ball
 Incubate for 50 min on horizontal rotator (180 min⁻¹) at ambient temperature
 Wash with 2 × 5 ml 0.15 mol/l NaCl containing 0.15 ml/l Tween 20
 200 µl donkey anti rabbit IgG labelled with N-(4-aminobutyl)-N-ethylisoluminol hemisuccinamide (1:150⁺ dilution)
 Incubate for 60 min on rotator and wash as above.
 Transfer balls to measuring cuvettes and proceed as in table 2.

+ represents dilution of labelled antibody as prepared in l.c. (2).
 * this step improved the precision of the assay.

Tab. 5. Thyroxine SPALT flow sheet.

25 µl sample or standard
 150 µl assay buffer (0.05 mol/l Tris-HCl containing 1.58 mmol/l 8-anilino-1-naphthalene sulphonic acid (ammonium salt), pH 7.5)
 100 µl rabbit anti thyroxine (1:500 dilution)
 Incubate for 60 min at ambient temperature
 1 Transferrin-thyroxine coated polystyrene ball*
 Incubate as above, but on horizontal rotator and wash with 2 × 1 ml wash buffer (0.05 mol/l Tris-HCl containing 0.15 ml/l Tween 20, pH 7.5)
 300 µl donkey anti rabbit IgG labelled with either pyruvate kinase or diazoluminol (1:50 dilution)
 Incubate for 60 min on horizontal rotator and wash with 1 ml wash buffer followed by 1 ml 0.15 mol/l NaCl. Transfer balls to measuring cuvettes and proceed with the light initiation step as in table 2.

* Synthesis of the thyroxine-transferrin conjugate has been described in l.c. (2).

The improvement in precision, shortening of assay time and semi-automation of all methods more than compensated for the additional cost of buying the equipment. Moreover, the trays could be re-used after washing without the precision and accuracy of the assay being influenced.

Results

Comparison of a CELIA and ILMA for thyroxine binding globulin (TBG)

Figure 1 shows standard curves for a TBG-CELIA and a TBG-ILMA. Table 6 shows the relevant assay and quality control data. The antibody bound to the solid phase was the same in each case as was the label used, in this case diazoluminol. The TBG used for labelling was identical with that used for making up the standards in both assays.




Fig. 1. Comparison between the thyroxine binding globulin CELIA (■—■) and ILMA (●—●). Both assays were measured on an LKB 1251 luminometer, the ordinate representing the integral of the light curve over 20 seconds. Each standard curve point is shown with the mean and 2 standard deviation (95% confidence-) limits.

Comparison between labelling using ILMA and ILSA for ferritin as examples

Figure 2 shows three standard curves using identical starting reagents. For the ILSA the second antibody (donkey anti-rabbit IgG) was labelled with diazoluminol (2), for the ILMAs both diazoluminol and N-(4-aminobutyl)-N-ethyl isoluminol hemisuccinamide were used to label the second anti-ferritin antibody. Table 7 shows relevant data from all three curves, here with special reference to the sensitivity (lowest detectable antigen level).

Comparison of different pH values to initiate the light reaction using a serum cortisol SPALT as an example

Table 8 shows a comparison between three cortisol SPALT assays set up at the same time with the same reagents. The difference between the assays is that one is oxidised at pH 8.6 to initiate the light reaction, the second with sodium hydroxide, directly after addition, and the third, after the solid phase has been left in contact with sodium hydroxide for 2 h. The assay flow sheet up until the light-reaction step is shown in table 9.

Tab. 6. Comparison of thyroxine binding globulin (TBG) CELIA and ILMA using diazoluminol as label.

Parameter	Assay 1 ⁺	Assay 2
Assay type	CELIA	ILMA
Sample size (μl)	50	1 (20 μl 1:20 dilution)
Standard matrix	Buffer	Buffer
Standard curve		
Counts ⁺⁺		
Zero standard (B ₀)	250	37
5 mg/l standard (B ₅)	150	65
80 mg/l standard (B ₈₀)	67	245
Ratios		
B ₀ /B ₈₀	3.73*	0.151
B ₅ /B ₀	0.60	1.76
B ₈₀ /B ₀	0.268	6.62*
Quality control		
Control sera (mg/l)**		
H1 (14 ± 3) (mean ± s.d.)	above 80	13.6
H2 (26 ± 5)	above 80	27.3
H3 (37 ± 6)	above 80	35.9
Correlation data*** with RIA		
No. of samples	—	89
Correlation coefficient r	—	0.985
Intercept a _{yx} (mg/l)	—	-2.74
Slope b _{yx}	—	0.976
Range of values used (mg/l)	—	10–43

⁺ Both assays were performed simultaneously.

⁺⁺ Expressed as mV · 20 s (integral)

* These values represent the dynamic range for the CELIA and ILMA respectively.

** The CELIA, although giving a standard curve, was unable to measure serum samples, and was therefore abandoned. Target values in brackets.

*** The correlation coefficient and related data was determined from a comparison with the Henning TBG-RIA, results from 6 assays being used. The RIA values were entered as x.




Fig. 2. Comparison of three ferritin assays using diazoluminol (△—△ ILSA; ■—■ ILMA) and N-(4-aminobutyl)-N-ethyl isoluminol hemisuccinamide (○—○ ILMA) labelled antibodies. Please note that the scales are not linear. The symbols and their significance are as in figure 1.

Tab. 7. Comparison of ferritin ILMA and ILSA using diazoluminol and N-(4-aminobutyl)-N-ethylisoluminol hemisuccinamide (ABEI-H) as labels – relevant assay data.

Parameter	ILMA-1 Label Diazoluminol	ILMA-2 ABEI-H	ILSA Diazoluminol
Counts⁺			
Zero standard (B ₀)	103	78	222
5 µg/l standard (B ₅)	–	125	–
10 µg/l standard (B ₁₀)	108	–	238
200 µg/l standard (B ₂₀₀)	155	1940	370
1000 µg/l standard (B ₁₀₀₀)	507	4210	965
Ratios of counts			
B ₅ /B ₀	–	1.60	–
B ₁₀ /B ₀	1.05	–	1.07
B ₂₀₀ /B ₀	1.50	24.9	1.67
B ₁₀₀₀ /B ₀ ⁺⁺	4.92	54.0	4.35
Spread of counts⁺⁺			
B ₁₀₀₀ – B ₀	404	4132	743
Sample size (µl)	100	20	100
Assay time (h)	24	6	26
Control serum values (µg/l)**			
D4 – target value 16 ± 1.9	30	16.4	19.0
D5 – target value 53 ± 4.2	55.0	48.3	52.4
D6 – target value 180 ± 6	192	164	177

⁺ Integral over 20 s, given in 1000 "Berthold light units"

⁺⁺ Expression of the dynamic range of the assay

* Represents the actual spread of counts between the lowest and highest standard.

** Values given as mean ± 1 standard deviation. The values given are the mean of duplicate values.

Tab. 8. Effect of pH and exposure time to sodium hydroxide on the light emission using the cortisol SPALT as an example.

Parameter	pH 8 ⁺	pH 13 ⁺ immediate	pH 13 ⁺ after 2 h
Light emission of zero standard (B ₀)	3294*	5391	20444
Light emission of unspecific binding (UB)	85*	103	441
Light emission of 2650 nmol/l standard (S ₂₆₅₀)	837*	1385	6726
Ratio UB/B ₀	0.03	0.02	0.02
Ratio S ₂₆₅₀ /B ₀	0.25	0.26	0.33
50% intercept (nmol/l)	660	473	908
Control serum D4 (nmol/l) ⁺⁺	154	132	143
Control serum D5	622	638	539
Control serum D6	1523	1413	1721

* Results in 1000 "Berthold Light Units"

⁺ All assays were set up at the same time. The results in column 2 were obtained when the tubes were processed directly after NaOH addition, those in column 3 when the light initiation step took place 2 h after NaOH addition. The results in column 1 were obtained when 0.5 mol/l phosphate buffer replaced the 1 mol/l NaOH.

⁺⁺ Results expressed are the mean of duplicate tubes.

Tab. 9. Cortisol SPALT flow sheet.

10 µl sample or standard
200 µl rabbit anti cortisol, 1:4000 in assay buffer (0.1 mol/l phosphate containing 0.1 mol/l sodium salicylate, pH 7.5)
1 cortisol-3-carboxymethyloxime-ovalbumin coated ball
Incubate on horizontal rotator (180 min ⁻¹) for 35 min at ambient temperature
Wash with 2 × 5 ml 0.15 mol/l NaCl containing 0.15 ml/l Tween 20
200 µl N-(4-aminobutyl)-N-ethylisoluminol hemisuccinamide labelled donkey anti rabbit IgG (1:180 dilution*)
Incubate as above, but for 45 min, wash as above and proceed as described in table 2 for the ball-transfer and light-initiating steps

* See table 4.

Comparison between pyruvate kinase and diazoluminol as label for the second antibody using a thyroxine SPALT as an example

The assay flow scheme has already been shown in table 5. Figure 3 shows standard curves for both assays, the relevant assay data being shown in table 10.




Fig. 3. Comparison of use of a bioluminescent (pyruvate kinase ■—■) label and a chemiluminescent label in a thyroxine SPALT. Both assays were measured on an LKB 1250 luminometer, the left-hand ordinate showing the chemiluminescent signal as 20 s integral, the right-hand ordinate the slope of the ATP-generation curve, expressed as mV/min.

Tab. 10. Comparison between a chemiluminescent and bioluminescent labelled SPALT assay for serum thyroxine.

Parameter	Assay 1*	Assay 2
Label	Diazoluminol	Pyruvate kinase
Standard curve		
<i>Counts</i>		
Zero standard (B_0)	240	3780
12 nmol/l standard (B_{12})	222	3280
410 nmol/l standard (B_{410})	66	674
Unspecific binding (UB)	31	202
<i>Ratios</i>		
UB/ B_0	0.130	0.053
B_{12}/B_0	0.925	0.868
B_{410}/B_0	0.275	0.178
B_0/B_{410}^{++}	3.64	5.61
<i>Intercepts (nmol/l)</i>		
80%	21.4	23.4
50%	64.8	57.4
20%	313	285
Quality control		
Serum A (27 ± 5) nmol/l**	21.1	24.0
Serum B (74 ± 10)	81.8	71.6
Serum C (166 ± 16)	165	157

* Counts for Assay 1 mV · 20 s (integral), for Assay 2 mV/min (slope)

** Expression of the assay dynamic range

* Assays set up at the same time and measured manually on an LKB 1250 Luminometer (see l.c. (1) and (2))

** Target values ± 1 standard deviation – results are the mean of duplicate determinations.

Clinical examples of routine luminescence immunoassays – data from a caeruloplasmin SPALT, a C-reactive protein ILSA and a ferritin ILMA

Figures 4 and 5 show typical standard curves for caeruloplasmin and C-reactive protein respectively. The label for the caeruloplasmin SPALT was N-(4-aminobutyl)-N-ethyl isoluminol hemisuccinamide, for C-reactive protein, diazoluminol. In both cases, the second antibody was labelled donkey anti-rabbit IgG. Table 11 shows clinical data obtained for different patient groups. The correlation between the ferritin assay here described and the radioimmunoassay used as its predecessor in the routine determination was excellent, ($n = 91$, $r = 0.992$, $a_{yx} = 0.071$ and $b_{yx} = 0.999$) when the same standards were used in each assay. Here the radioimmunoassay values were entered as x, those from the ILMA as y. The range of the values used for this calculation were 5–570 $\mu\text{g/l}$ for the RIA and 3–567 $\mu\text{g/l}$ for the ILMA.




Fig. 4. Caeruloplasmin SPALT measured on the Berthold LB-950 luminometer. The ordinate represents the 20 s integral, expressed here in "Berthold light units" $\times 10^6$, as this luminometer employs photon counting techniques rather than the current amplification method used in the LKB instruments.




Fig. 5. C-reactive protein ILSA, using a diazoluminol labelled second antibody (donkey anti-rabbit IgG). This assay was measured on an LKB 1251 luminometer, the ordinate showing the 20 s integral value.

Tab. 11. Assay parameters and values from three experimental groups for caeruloplasmin, C-reactive protein and ferritin assays.

Parameter	Caerulo- plasmin	C-reactive protein	Ferritin
Assay type	SPALT	ILSA	ILMA
Label	ABEI-H ⁺	Diazoluminol	ABEI-H ⁺
Standard matrix	Buffer	Serum	Buffer
Standard	Human CP ⁺	Human CRP ⁺	Human LF ⁺
Reference range (serum)	0.15–0.65 g/l	under 5 mg/l	30–300 µg/l
Assay working range ⁺⁺	0.15–1.25 g/l	2–160 mg/l	5–1000 µg/l
Mean precision (%) ⁺⁺⁺	5.8 (n = 205)	4.2 (n = 99)	4.3 (n = 1254)
Lower detection limit	<0.08 g/l	<1 mg/l	<2 µg/l
Experimental groups			
<i>Crohn/Colitis</i>			
Range	0.14–0.53 g/l	1.72–60.2 mg/l	2–911 µg/l
Median	0.30 g/l	22.9 mg/l	23.8 µg/l
No. of elevated values*	0	18	4
No. of reduced values*	1	–	23
No. of patients in group	12	21	40
<i>Tumour bearers**</i>			
Range	0.13–2.34	0.8–139	3–2440
Median	0.44	11.8	152
No. of elevated values	12	14	14
No. of reduced values	1	–	4
No. of patients in group	35	18	42
<i>Blood donors – unselected</i>			
Range	0.06–1.01	0.5–10.7	5–240
Median	0.26	0.91	58
No. of elevated values	3	3	0
No. of reduced values	4	–	16
No. in group	45	64	84

⁺ CP = caeruloplasmin, CRP = C-reactive protein, LF = liver ferritin, ABEI-H = N-(4-aminobutyl)-N-ethyl isoluminol hemisuccinamide

⁺⁺ Range in which the mean precision is under 10%

⁺⁺⁺ Actual precision within the working range – mean of all patients (n = . . .)

* Values lying below or above the established reference range.

** Pre-operative values – only patients with surgically confirmed tumours used in this analysis.

Discussion

The aim of this paper has been to put into practice some of the experiments performed in the first two parts of this series (1, 2). A comparison of both labels and methods has been made using a wide variety of antigens as ligands. Detailed clinical trials and evaluation results have been avoided, results being limited to a few assays, especially those shown in table 11.

The future of the luminescence immunoassay lies in its field of application, especially where its role as a practical alternative to routine radioimmunoassays is concerned. The assays presented here represent the whole gamut of molecular size and concentration found in in-vitro clinical chemistry and endocrinology.

The results of the comparison between a CELIA and ILMA using the same label and components (diazoluminol and immobilised sheep anti TBG) shows the relative sensitivity and working range of the two assay types, here for thyroxine binding globulin. The larger working range of the ILMA agrees with the findings of *Hunter* (6) who compared radioimmunoassays and immunoradiometric assays for sensitivity and working range. The TBG CELIA, although giving a dose response curve when the standards were dissolved in a buffer matrix, was unable to be used for measuring serum samples, where all values lay above the highest standard. The combination of the relatively large sample volume (50 µl) and contact between serum and label may be a crucial factor with the CELIA, as the TBG ILMA, where a much smaller sample (1 µl) was used, and where serum and label did not come into contact, measured correctly. Similar problems were encountered with a thyroxine CELIA using larger serum volumes (50 µl) and low-titer low affinity antibodies (*Gadow*, unpublished results).

The comparison between the different labels is well demonstrated in the case of the ferritin assays (table 7, figure 2). Although the detection limits of free diazoluminol and N-(4-aminobutyl)-N-ethyl isoluminol hemisuccinamide were similar (2), the N-(4-aminobutyl)-N-ethyl isoluminol hemisuccinamide label allowed an assay to be developed which was sensitive enough for routine use. This was probably due to the difference in the chemical coupling methods used, the N-(4-aminobutyl)-N-ethyl isoluminol hemisuccinamide active ester being under neutral and mild reaction conditions, the diazo coupling taking place in alkaline solution over a period of several hours. The ferritin assays show the relative performance of ILMA and ILSA using the same label (here diazolu-

minol). The dynamic range of the N-(4-aminobutyl)-N-ethyl isoluminol hemisuccinamide labelled ferritin ILMA is far greater than that using diazoluminol as label. This is reflected in the ratio between the number of counts in the highest standard and those in the zero standard, (see tab. 7). This ratio was 54:1 for N-(4-aminobutyl)-N-ethyl isoluminol hemisuccinamide labelled anti ferritin and only 4.9:1 for diazoluminol labelled anti ferritin.

Various conditions have been described for the optimal conditions for light emission which range from initiation at pH 8–9 (7) via pH 13 (4) to initiation after standing in alkaline solution for several minutes (8) to a few hours (Kohen, personal communication). The cortisol SPALT (see tab. 8 and 9) was used to compare the effect of pH and alkaline incubation on the light output. Although the signal increases between pH 8 and pH 13 as well as between pH 13 when measured immediately and after 2 h standing in sodium hydroxide, the signal to noise ratio, expressed in terms of the zero standard (B_0) and unspecific binding (UB) increased only slightly.

The dynamic range of the assay, expressed as the light signal given by the zero standard and that given by the highest standard, remained almost unchanged between pH 8 and pH 13, and was noticeably reduced after prolonged alkaline incubation before light initiation.

The values of the control sera lay within the expected limits for all assays.

The thyroxine SPALT was used to demonstrate the use of bioluminescent and chemiluminescent labels. The bioluminescent SPALT had a larger dynamic range when compared with the diazoluminol labelled assay, and was potentially more sensitive, as can be seen from the intercept values (tab. 10). Both assays measured correctly in terms of the control sera. Replacement of the diazoluminol labelled second antibody by one labelled with N-(4-aminobutyl)-N-ethyl

isoluminol hemisuccinamide gave rise to a similar increase in the dynamic range as seen in the ferritin ILMA, so that for the routine assay, N-(4-aminobutyl)-N-ethyl isoluminol hemisuccinamide was chosen as label.

As stated above, the proof of the assays is in their clinical routine application and examples have been presented for ferritin, C-reactive protein and caeruloplasmin, all of which are the only routine assay for these components. The results shown are taken from projects on patients with tumours and with *Crohn's* disease or ulcerative colitis (see tab. 11). The screening of blood donors is part of an ongoing routine procedure, especially upon new and regular donors.

The mean precision within the working range, here derived from compound precision profiles, was acceptable and comparable with commercial tests. A further advantage of these tests was their suitability for paediatric use, the largest sample volume being 20 μ l for ferritin.

One thing became clear when working with immobilised antibodies, and that was the necessity for partial purification of the native antisera before coupling to the solid phase. This was effected by precipitation of the γ -globulin fraction with 200 g/l polyethylene glycol (M_r 6000) with resolution of the precipitate in 0.02 mol/l phosphate buffer, pH 8. Subsequent passage over a DEAE-cellulose column was sufficient to give a product with acceptable purity.

To conclude, it has been shown that the application of luminescence immunoassays in routine in-vitro diagnosis is now possible, although the acceptance of such assays still depends upon the commercialisation of the methods.

Acknowledgements

The authors wish to thank Frau *Jutta Jäger* for technical assistance.

References

1. Wood, W. G. & Gadow, A. (1983) *J. Clin. Chem. Clin. Biochem.* 21, 789–797.
2. Gadow, A., Fricke, H. & Wood, W. G. (1984) *J. Clin. Chem. Clin. Biochem.* 22, 337–347.
3. Miles, L. E. M. & Hales, C. N. (1968) *Nature* 219, 186.
4. Strasburger, C. J., Fricke, H. & Wood, W. G. (1982) In: *Radioimmunoassay and related procedures in medicine 1982*, IAEA, Vienna, pp. 757–777.
5. Wood, W. G., Fricke, H., von Klitzing, L., Strasburger, C. J. & Scriba, P. C. (1982) *J. Clin. Chem. Clin. Biochem.* 20, 825–831.
6. Hunter, W. M. (1982) In: *Radioimmunoassay and related procedure in medicine 1982*, IAEA, Vienna, pp. 3–21.
7. Kohen, F., Kim, J. B. & Lindner, H. R. (1981) In: *Bioluminescence and chemiluminescence, basic chemistry and analytical applications* (DeLuca, Marlene A., McElroy, W. D., eds.) Academic Press, New York, pp. 357–364.
8. Strasburger, C. J., Fricke, H. & Wood, W. G. (1982) *Fresenius Z. Anal. Chem.* 311, 351–352.

Priv.-Doz. Dr. W. G. Wood
Klinische Laboratorien
Klinik für Innere Medizin
Medizinische Hochschule Lübeck
Ratzeburger Allee 160
D-2400 Lübeck 1